0001000228-20-000018 | 10-K | XBRL Viewer

Less: Deferred debt issuance costs

$ (155)

Long-term Debt and finance Lease Obligations, Including Current Maturities

732,757

$ 988,624

Private placement facilities [Member]

Less: Deferred debt issuance costs

(155)

Long-term Debt and finance Lease Obligations, Including Current Maturities

$ 621,274

$ 628,189

Private placement facilities [Member] | Private placement facilities maturing in September 2020 [Member]

Sep. 15, 2020

Sep. 02, 2010

$ 100,000

3.79%

Private placement facilities [Member] | Private placement facilities maturing in January 2024 [Member]

Sep. 02, 2020

Jan. 20, 2012

$ 50,000

3.45%

Private placement facilities [Member] | Private placement facilities maturing in January 2022 [Member]

Jan. 20, 2024

Jan. 20, 2012

^[1]

$ 21,429

3.09%

Private placement facility, repayment frequency

Jan. 20, 2022

Annual

Private placement facility, annual payment

$ 7,100

Debt Instrument, Date of First Required Payment

Jan. 20, 2016

Private placement facilities [Member] | Private placement facilities maturing in December 2024 [Member]

Dec. 24, 2012

$ 50,000

3.00%

Private placement facilities [Member] | Private placement facilities maturing in June 2021 [Member]

Dec. 24, 2024

Jun. 02, 2014

$ 100,000

3.19%

Private placement facilities [Member] | Private Placement facilities maturing in June 2027 [Member]

Jun. 02, 2021

Jun. 16, 2017

$ 100,000

3.42%

Private placement facilities [Member] | Private Placement Facilities maturing in September 2029 [Member]

Jun. 16, 2027

Sep. 15, 2017

$ 100,000

3.52%

Private placement facilities [Member] | Private Placement facilities maturing in January 2028 [Member]

Sep. 15, 2029

Jan. 02, 2018

$ 100,000

3.32%

Summary of the stock option activity under the plans

Jan. 02, 2028

[1]	(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 29, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (20,338)				$ (18,595)				$ (20,338)	$ (18,595)	$ (5,564)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(531)				(426)				(531)	(426)	539
Attributable to Henry Schein, Inc.:
Foreign currency translation gain (loss)	(143,172)				(234,799)				(143,172)	(234,799)	(112,439)
Unrealized gain (loss) from foreign currency hedging activities	(4,032)				(156)				(4,032)	(156)	(782)
Unrealized investment gain (loss)	6				(6)				6	(6)	(3)
Pension adjustment gain (loss)	(20,175)				(13,810)				(20,175)	(13,810)	(16,843)
Accumulated other comprehensive income (loss)	(167,373)				(248,771)				(167,373)	(248,771)	(130,067)
Total Accumulated other comprehensive income (loss)	(188,242)				(267,792)				(188,242)	(267,792)	(135,092)
Components of comprehensive income [Abstract]
Net income	$ 337,192	$ 143,212	$ 121,417	$ 123,640	$ 124,886	$ 96,247	$ 114,591	$ 114,717	719,138	562,126	459,293
Foreign currency translation gain (loss)									(4,070)	(136,356)	191,886
Tax effect									0	0	0
Foreign currency translation gain (loss)									(4,070)	(136,356)	191,886
Unrealized gain (loss) from foreign currency hedging activities									(4,911)	1,022	(1,515)
Tax effect									1,035	(396)	786
Unrealized gain (loss) from foreign currency hedging activities									(3,876)	626	(729)
Unrealized investment gain (loss)									14	(3)	(4)
Tax effect									(2)	0	1
Unrealized investment gain (loss)									12	(3)	(3)
Pension adjustment gain (loss)									(7,730)	4,212	4,247
Tax effect									1,806	1,179	(314)
Pension adjustment gain (loss)									(5,924)	3,033	3,933
Comprehensive income									$ 705,280	$ 429,426	$ 654,380

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 28, 2019

	Years Ended
	December 28,			December 29,			December 30,
	2019			2018			2017

		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at beginning of year	3	$	13.63	155	$	29.65	353	$	28.59
Granted	-		-	-		-	-		-
Exercised	(3)		13.63	(152)		29.81	(198)		27.76
Forfeited	-		-	-		-	-		-
Outstanding at end of year	-	$	-	3	$	17.22	155	$	29.65

Options exercisable at end of year	-	$	-	3	$	17.22	155	$	29.65

Intrinsic values

	As of
	December 28,		December 29,		December 30,
	2019		2018		2017
Stock options outstanding	$	-	$	121	$	6,256
Stock options exercisable		-		121		6,256

Status of non-vested restricted shares/units


	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,513	$	57.94
Granted	452		59.56
Vested	(339)		55.62
Forfeited	(208)		60.35
Outstanding at end of period	1,418	$	58.72	$	66.58
	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,163	$	40.26
Granted	642		59.72
Vested	(189)		66.41
Forfeited	(157)		61.33
Outstanding at end of period	1,459	$	61.41	$	66.58

Debt

12 Months Ended

Dec. 28, 2019

Debt [Abstract]

Debt

Note 6 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

	December 28,		December 29,
	2019		2018
Revolving credit agreement	$	-	$	175,000
Other short-term bank credit lines		23,975		376,458
Committed loan associated with Animal Health spin-off		-		400,000
Total	$	23,975	$	951,458

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”), which matures in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect that the LIBOR rate will be discontinued at some point during 2021. We expect to work with our lenders to identify a suitable replacement rate and amend our debt agreements to reflect this new reference rate accordingly. We do not believe that the discontinuation of LIBOR as a reference rate in our debt agreements will have a material adverse effect on our financial position or materially affect our interest expense. Additionally, the Credit Agreement provides, among other things, that we are required to maintain maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of December 28, 2019 and December 29, 2018, the borrowings on this revolving credit facility were $0.0 million and $175.0 million, respectively. As of December 28, 2019 and December 29, 2018, there were $9.6 million and $11.2 million of letters of credit, respectively, provided to third parties under the credit facility.

Other Short-Term Credit Lines

As of December 28, 2019 and December 29, 2018, we had various other short-term bank credit lines available, of which $24.0 million and $376.5 million, respectively, were outstanding. At December 28, 2019 and December 29, 2018, borrowings under all of our credit lines had a weighted average interest rate of 3.45% and 3.30%, respectively.

Committed Loan Associated with Animal Health Spin-off

On May 21, 2018, we obtained a $400 million committed loan which matured on the earlier of (i) March 31, 2019 and (ii) the consummation of the Animal Health Spin-off. The proceeds of this loan were used, among other things, to fund our purchase of all of the equity interests in Butler Animal Health Holding Company, LLC (“BAHHC”) directly or indirectly owned by Darby Group Companies, Inc. (“Darby”) and certain other sellers pursuant to the terms of that certain Amendment to Put Rights Agreements, dated as of April 20, 2018, by and among us, Darby, BAHHC and the individual sellers party thereto for an aggregate purchase price of $365 million. As of December 29, 2018, the balance outstanding on this loan was $400 million and is included within the “Bank credit lines” caption within our consolidated balance sheet. At December 29, 2018, the interest rate on this loan was 3.38%. Concurrent with the completion of the Animal Health Spin-off on February 7, 2019, we re-paid the balance of this loan.

Long-term debt

Long-term debt consisted of the following:

		December 28,		December 29,
		2019		2018
Private placement facilities		$	621,274	$	628,189
U.S. trade accounts receivable securitization			100,000		350,000
Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2024 at interest rates
	ranging from 2.56% to 10.5% at December 28, 2019 and
	ranging from 2.61% to 4.17% at December 29, 2018		6,089		6,491
Finance lease obligations (see Note 7)			5,394		3,944
Total			732,757		988,624
Less current maturities			(109,849)		(8,280)
	Total long-term debt	$	622,908	$	980,344

Private Placement Facilities

On September 15, 2017, we increased our available private placement facilities with three insurance companies to a total facility amount of $1 billion, and extended the expiration date to September 15, 2020. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through September 15, 2020. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above private placement facilities to, among other things, (i) permit the consummation of the Animal Health Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

The components of our private placement facility borrowings as of December 28, 2019 are presented in the following table (in thousands):


	Amount of
Date of	Borrowing		Borrowing
Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012 (1)		21,429	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
June 2, 2014		100,000	3.19		June 2, 2021
June 16, 2017		100,000	3.42		June 16, 2027
September 15, 2017		100,000	3.52		September 15, 2029
January 2, 2018		100,000	3.32		January 2, 2028
Less: Deferred debt issuance costs		(155)
	$	621,274

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, and was previously scheduled to expire on April 29, 2020, has been extended to April 29, 2022. As of December 28, 2019 and December 29, 2018, the borrowings outstanding under this securitization facility were $100 million and $350 million, respectively. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 1.90% plus 0.75%, for a combined rate of 2.65%. At December 29, 2018, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 2.66% plus 0.75%, for a combined rate of 3.41%.

We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.

Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheet.

As of December 28, 2019, the aggregate amounts of long-term debt, including finance lease obligations and net of deferred debt issuance costs of $155, maturing in each of the next five years and thereafter are as follows:

2020		$	109,849
2021			108,842
2022			110,504
2023			1,529
2024			101,112
Thereafter			300,921
	Total	$	732,757

Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018
Debt Instrument [Line Items]
Total Long-term debt	$ 732,757	$ 988,624
Less current maturities	(109,849)	(8,280)
Long-term debt	622,908	980,344
Finance lease obligations (See Note 7)	5,394	3,944
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Total Long-term debt	621,274	628,189
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Total Long-term debt	100,000	350,000
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member]
Debt Instrument [Line Items]
Total Long-term debt	$ 6,089	$ 6,491
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.56%	2.61%
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	10.50%	4.17%

Plans of Restructuring - Restructuring Reserve Roll Forward by Expense and Segment (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 29, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				$ 31,725				$ 4,426	$ 31,725	$ 4,426	$ 22,650
Provision	$ (1,059)	$ (802)	$ 11,925	4,641	$ 34,644	$ 8,551	$ 8,497	2,675	14,705	54,367	0
Payments and other adjustments									(32,620)	(27,068)	(18,224)
Restructuring Reserve, ending balance	13,810				31,725				13,810	31,725	4,426
Health Care Distribution [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				30,291				4,426	30,291	4,426	22,505
Provision									13,935	50,824	0
Payments and other adjustments									(30,853)	(24,959)	(18,079)
Restructuring Reserve, ending balance	13,373				30,291				13,373	30,291	4,426
Technology and Value-Added Services [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				1,434				0	1,434	0	145
Provision									770	3,543	0
Payments and other adjustments									(1,767)	(2,109)	(145)
Restructuring Reserve, ending balance	437				1,434				437	1,434	0
Severance costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				29,964				3,087	29,964	3,087	20,447
Provision									13,741	50,197	0
Payments and other adjustments									(30,794)	(23,320)	(17,360)
Restructuring Reserve, ending balance	12,911				29,964				12,911	29,964	3,087
Facility closing costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				1,603				1,315	1,603	1,315	2,130
Provision									937	3,153	0
Payments and other adjustments									(1,714)	(2,865)	(815)
Restructuring Reserve, ending balance	826				1,603				826	1,603	1,315
Other [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				$ 158				$ 24	158	24	73
Provision									27	1,017	0
Payments and other adjustments									(112)	(883)	(49)
Restructuring Reserve, ending balance	$ 73				$ 158				$ 73	$ 158	$ 24

Income Taxes - Operating Loss Carryforwards (Details) $ in Millions	12 Months Ended
	Dec. 28, 2019 USD ($)
Foreign tax authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards subject to amortization	$ 2.0
Net operating loss carryforwards not subject to expiration	$ 144.9
Net operating loss carryforwards, year of expiration	Dec. 31, 2026
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards subject to amortization	$ 14.3
Net operating loss carryforwards not subject to expiration	$ 21.1
Net operating loss carryforwards, year of expiration	Dec. 31, 2039

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017	Dec. 31, 2016
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 287,258	$ 219,724	$ 465,585	$ 285,567
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	756,700	1,940,100
Fair value, measurements, recurring [Member]
Assets [Abstract]
Derivative contracts - assets	567	12,533
Total assets	567	12,533
Liabilities [Abstract]
Derivative contracts - liabilities	5,795	1,708
Total liabilities	5,795	1,708
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	287,258	219,724
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Derivative contracts - assets	567	12,533
Total assets	567	12,533
Liabilities [Abstract]
Derivative contracts - liabilities	5,795	1,708
Total liabilities	5,795	1,708
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 287,258	$ 219,724

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Operating Leases
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets	$ 231,662,000	$ 0
Operating lease liabilities	$ 241,616,000
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	364 days	364 days	364 days
Outstanding checks in excess of funds on deposit classified as accounts payable	$ 29,500,000	$ 41,100,000
Costs of goods sold	6,894,917,000	6,506,856,000	$ 6,136,776,000
Advertising and promotional costs	25,200,000	12,900,000	800,000
Goodwill impairment loss	0	0	0
Total distribution network costs	72,300,000	69,600,000	67,500,000
Income taxes	(159,515,000)	(107,432,000)	(308,975,000)
Contract with Customer, Liability, Current	70,800,000	65,300,000
Contract with Customer, Liability, Noncurrent	6,200,000	5,000,000.0
Direct shipping and handling costs [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Costs of goods sold	73,800,000	70,600,000	$ 65,000,000.0
Variable Interest Entity, Primary Beneficiary [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entity, Consolidated, Assets, Pledged	127,000,000	422,000,000
Variable Interest Entity, Consolidated, Liabilities, Recourse	$ 100,000,000	$ 350,000,000
Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	364 days
Percentage ownership of subsidiaries included in consolidated tax return	80.00%	80.00%	80.00%
Maximum [Member]
Operating Leases
Lessee, Operating Lease, Option to Extend	may include options to extend the leases for up to 10 years
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	371 days
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated [true false]	true
Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Fixed List]	Modified Retrospective
Operating lease right-of-use assets		$ 259,900,000
Operating lease liabilities		$ 267,300,000
Decrease in prepaid rent	$ 1,100,000
Decrease in deferred rent liabilities	$ 8,500,000
Lease, Practical Expedients, Package [true false]	true
Accounting Standards Update 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated [true false]	true
Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Fixed List]	Modified Retrospective
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Dec. 31, 2017
Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]	true
Accounting Standards Update 2017-12 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true

Debt - Maturities (Details) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018
Maturities of Long-term Debt [Abstract]
2019	$ 109,849
2020	108,842
2021	110,504
2022	1,529
2023	101,112
Thereafter	300,921
Total Long-term debt	732,757	$ 988,624
Debt Instrument [Line Items]
Debt Issuance Costs, Gross	155
Private Placement Facilities [Member]
Maturities of Long-term Debt [Abstract]
Total Long-term debt	621,274	$ 628,189
Debt Instrument [Line Items]
Debt Issuance Costs, Gross	$ 155

Concentrations of Risk

12 Months Ended

Dec. 28, 2019

Risks and Uncertainties [Abstract]

Concentrations of Risk

Note 15 – Concentrations of Risk

Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial instruments. We continuously assess the need for reserves for such losses, which have been within our expectations. We do not require collateral or other security to support financial instruments subject to credit risk, except for long-term notes receivable.

We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counter-parties.

With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base and its dispersion across different types of health care professionals and geographic areas. For the years ended December 28, 2019 and December 29, 2018 one customer accounted for slightly more than 1% of our net sales from continuing operations. With respect to our sources of supply, our top 10 health care distribution suppliers from continuing operations and our single largest supplier from continuing operations accounted for approximately 31% and 6%, respectively, of our aggregate purchases in 2019 and approximately 31% and 6%, respectively, of our aggregate purchases in 2018.

Our long-term notes receivable primarily represent strategic financing arrangements with certain industry affiliates and amounts owed to us from sales of certain businesses. Generally, these notes are secured by certain assets of the counter-party; however, in most cases our security is subordinate to other commercial financial institutions. While we have exposure to credit loss in the event of non-performance by these counter-parties, we conduct ongoing assessments of their financial and operational performance.

Earnings Per Share (Tables)

12 Months Ended

Dec. 28, 2019

Earnings Per Share [Abstract]

Reconciliation of basic and diluted shares used to calculate earnings per share

		Years Ended
		December 28,	December 29,	December 30,
		2019	2018	2017
Basic		147,817	152,656	156,787
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,440	1,051	1,421
	Diluted	149,257	153,707	158,208

Debt - Private Placement Facilities - Narrative (Details) - Private placement facilities [Member] - USD ($)		12 Months Ended
	Sep. 15, 2017	Dec. 28, 2019
Debt Instrument [Line Items]
Debt Instrument Maximum Borrowing Capacity		$ 1,000,000,000
Debt Instrument, Maturity Date	Sep. 15, 2020
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		15 years
Average term of issuances under private placement facilities		12 years

Income Taxes

12 Months Ended

Dec. 28, 2019

Income Taxes [Abstract]

Income Taxes

Note 14 – Income Taxes

		Years ended
		December 28,		December 29,		December 30,
		2019		2018		2017
Domestic		$	507,003	$	405,289	$	526,586
Foreign			173,304		131,547		103,208
	Total	$	680,307	$	536,836	$	629,794

The provisions for income taxes were as follows:

				Years ended
				December 28,		December 29,		December 30,
				2019		2018		2017
Current income tax expense:
	U.S. Federal			$	93,418	$	71,854	$	247,254
	State and local				28,150		22,533		19,489
	Foreign				42,004		38,433		41,043
		Total current			163,572		132,820		307,786

Deferred income tax expense (benefit):
	U.S. Federal				5,633		206		12,927
	State and local				1,597		(1,622)		1,621
	Foreign				(11,287)		(23,972)		(13,359)
		Total deferred			(4,057)		(25,388)		1,189
			Total provision	$	159,515	$	107,432	$	308,975

The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows:

			Years Ended
			December 28,		December 29,
			2019		2018

Deferred income tax asset:
	Investment in partnerships		$	1,420	$	4,150
	Net operating losses and other carryforwards			43,663		43,754
	Inventory, premium coupon redemptions and accounts receivable
		valuation allowances		23,808		25,008
	Stock-based compensation			14,075		14,880
	Uniform capitalization adjustment to inventories			7,259		8,189
	Other asset			35,419		38,806
	Total deferred income tax asset			125,644		134,787
	Valuation allowance for deferred tax assets (1)			(20,699)		(22,403)
	Net deferred income tax asset			104,945		112,384
Deferred income tax liability
	Intangibles amortization			(135,754)		(103,309)
	Property and equipment			(10,555)		(13,075)
	Total deferred tax liability			(146,309)		(116,384)
Net deferred income tax asset (liability)			$	(41,364)	$	(4,000)


(1)	Primarily relates to operating losses of acquired subsidiaries, the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense in accordance with the provisions of ASC Topic 805, “Business Combinations.”

The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and the results of recent operations. Since this evaluation requires consideration of events that may occur some years into the future, there is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than not that we will be able to recover all of the value assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly.As of December 28, 2019, we had foreign net operating loss carryforwards of $2.0 million, which can be utilized against future foreign income through December 31, 2026. Additionally, as of December 28, 2019, there were foreign net operating loss carryforwards of $144.9 million that have an indefinite life. As of December 28, 2019, the company had post-apportionment state net operating loss carryforwards of $14.3 million, which can be utilized against future state income through December 31, 2039. Additionally, as of December 28, 2019, there were post-apportionment state operating loss carryforwards of $21.1 million that have an indefinite life.The tax provisions differ from the amount computed using the federal statutory income tax rate as follows:

		Years ended
		December 28,		December 29,		December 30,
		2019		2018		2017
Income tax provision at federal statutory rate		$	142,865	$	112,735	$	220,427
State income tax provision, net of federal income tax effect			16,539		15,872		10,320
Foreign income tax benefit			(4,580)		(2,558)		(19,486)
Pass-through noncontrolling interest			(3,931)		(2,700)		(1,465)
Valuation allowance			(79)		2,017		1,629
Unrecognized tax benefits and audit settlements			3,671		2,126		4,196
Interest expense related to loans			(5,498)		(11,700)		(18,492)
Excess tax benefits related to stock compensation			(86)		(1,008)		(16,964)
Transition tax on deemed repatriation of foreign earnings			-		(10,000)		140,000
Revaluation of deferred tax assets and liabilities			-		(1,676)		2,953
Tax on global intangible low-taxed income ("GILTI")			3,917		7,599		-
Tax benefit related to legal entity reorganization outside the U.S.			-		(13,852)		-
Tax charge related to reorganization of legal entities related
to forming Henry Schein One			-		3,914		-
Tax charge (credit) related to reorganization of legal entities
completed in preparation for the Animal Health spin-off			(1,333)		3,135		-
Other			8,030		3,528		(14,143)
	Total income tax provision	$	159,515	$	107,432	$	308,975

For the year ended December 28, 2019, our effective tax rate was 23.4% compared to 20.0% for the prior year period. In 2019, our effective tax rate was primarily impacted by state and foreign income taxes and interest expense. In 2018, our effective tax rate was primarily impacted by a reduction in the estimate of our transition tax associated with the Tax Act, tax charges and credits associated with legal entity reorganizations outside the U.S., and state and foreign income taxes and interest expense. In 2017, our effective tax rate was primarily impacted by the Tax Act, the adoption of ASU 2016-09, as well as state and foreign income taxes and interest expense.

On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35% to 21%, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. In the fourth quarter of 2017, we recorded provisional amounts for any items that could be reasonably estimated at the time. This included the one-time transition tax that we estimated to be $140.0 million and a net deferred tax expense of $3.0 million attributable to the revaluation of deferred taxes due to the lower enacted federal income tax rate of 21%. We completed our analysis in the year ended December 29, 2018 and recorded a net $10.0 million reduction to the one-time transition tax and an additional $1.7 million net deferred tax benefit from the revaluation of deferred taxes to reflect the new tax rate. Absent the effects of the transition tax and the revaluation of deferred tax assets and liabilities, our effective tax rate for the year ended December 30, 2017 would have been 26.4% as compared to our actual effective tax rate of 49.1%.

Within our consolidated balance sheets, transition tax of $9.9 million was included in “Accrued taxes” for 2019 and 2018, and $94.9 million and $104.2 million were included in “Other liabilities” for 2019 and 2018, respectively.

The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income (“GILTI”), states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. We recorded a current tax expense for the GILTI provision of $7.6 million and $3.9 million for 2018 and 2019, respectively.

Due to the one-time transition tax and the imposition of the GILTI provisions, all previously unremitted earnings will no longer be subject to U.S. federal income tax; however, there could be U.S. state and/or foreign withholding taxes upon distribution of such unremitted earnings. Determination of the amount of unrecognized deferred tax liability with respect to such earnings is not practicable.

ASC 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect to certain tax matters.

The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets as of December 28, 2019 was approximately $109.1 million, of which $91.2 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits may change in the next 12 months, which may result in a material impact on our consolidated statement of income.

The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the U.S. Internal Revenue Service (“IRS”), as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2011. We are currently under audit for the years 2012 and 2013. In the quarter ended December 28, 2019, we reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and 2013. For all remaining outstanding issues for 2012 and 2013, we have provided all necessary documentation to the Appellate Division to date and are waiting for responses. We are also in negotiations with the Advanced Pricing Division to reach an agreement on an appropriate transfer pricing methodology. As part of this process, we have submitted documentation with the objective to reach a resolution for 2014-2021 in order to mitigate future transfer pricing audit adjustments. It is possible that the resolution with the IRS may have a material impact on our consolidated financial statements.

The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense (credits) was approximately $2.2 million, $3.6 and $(2.9) in 2019, 2018 and 2017, respectively. The total amount of accrued interest is included in “Other liabilities”, and was approximately $18.0 million as of December 28, 2019 and $15.6 million as of December 29, 2018. No penalties were accrued for the periods presented.

The following table provides a reconciliation of unrecognized tax benefits:

	December 28,		December 29,		December 30,
	2019		2018		2017
Balance, beginning of period	$	77,800	$	83,200	$	82,200
Additions based on current year tax positions		4,900		5,000		8,500
Additions based on prior year tax positions		17,300		9,400		5,400
Reductions based on prior year tax positions		(1,000)		(1,600)		(800)
Reductions resulting from settlements with taxing authorities		(4,200)		(1,600)		(10,500)
Reductions resulting from lapse in statutes of limitations		(3,700)		(16,600)		(1,600)
Balance, end of period	$	91,100	$	77,800	$	83,200

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 28, 2019

Commitments and Contingencies Disclosure [Abstract]

Purchase commitments

2020		$	403,241
2021			208,200
2022			110,800
2023			-
2024			-
Thereafter			-
	Total minimum inventory purchase commitment payments	$	722,241

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 07, 2019	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off		$ 1,120,000	$ 0	$ 0
Proceeds related to Animal Health Share Sale		$ 361,090	$ 0	$ 0
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Henry Schein stockholders and the Share Sale Investors [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	37.00%
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Vets First Corp [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off	$ 1,120,000
Proceeds related to Animal Health Share Sale	$ 361,100
Noncontrolling Interest, Ownership Percentage by Parent	63.00%

Derivatives and Hedging Activities (Details) € in Millions	12 Months Ended
Derivatives and Hedging Activities (Details) € in Millions	Dec. 28, 2019 EUR (€)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Maximum duration of foreign currency forward contracts	18 months
Net Investment Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	€ 200
Derivative, Maturity Dates	Nov. 16, 2023

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 798,591	$ 905,105
Less accumulated depreciation and amortization	(468,946)	(590,884)
Property and equipment, net	329,645	314,221
Property and equipment related depreciation expense	64,400	58,100	$ 54,700
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,030	17,985
Buildings and permanent improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 121,823	127,012
Property and equipment, average useful life (in years)	40 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 104,089	103,929
Machinery and warehouse equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 124,640	108,249
Machinery and warehouse equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	5 years
Machinery and warehouse equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 99,083	120,693
Furniture, fixtures and other [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Furniture, fixtures and other [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 330,926	$ 427,237
Computer equipment and software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Computer equipment and software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 28, 2019

Revenue from Contracts with Customers [Abstract]

Disaggregation of Revenue

				Year Ended
				December 28, 2019
				North America		International		Global
Revenues:
	Health care distribution
		Dental		$	3,911,746		2,504,119		6,415,865
		Medical			2,894,137		79,449		2,973,586
			Total health care distribution		6,805,883		2,583,568		9,389,451
	Technology and value-added services				445,317		69,768		515,085
	Total excluding Corporate TSA revenues⁽¹⁾				7,251,200		2,653,336		9,904,536
	Corporate TSA revenues⁽¹⁾				4,098		77,169		81,267
		Total revenues		$	7,255,298	$	2,730,505	$	9,985,803

				Year Ended
				December 29, 2018
				North America		International		Global
Revenues:
	Health care distribution
		Dental		$	3,866,171		2,481,827		6,347,998
		Medical			2,581,696		79,470		2,661,166
			Total health care distribution		6,447,867		2,561,297		9,009,164
	Technology and value-added services				344,168		64,271		408,439
	Total excluding Corporate TSA revenues⁽¹⁾				6,792,035		2,625,568		9,417,603
	Corporate TSA revenues⁽¹⁾				-		-		-
		Total revenues		$	6,792,035	$	2,625,568	$	9,417,603

(1)

Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement

entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

Debt - Bank Credit Lines (Details) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018
Line of Credit Facility [Line Items]
Bank credit lines	$ 23,975	$ 951,458
Revolving credit facility [Member]
Line of Credit Facility [Line Items]
Bank credit lines	0	175,000
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines	23,975	376,458
Committed Loan Associated with Animal Health Spin-off [Member]
Line of Credit Facility [Line Items]
Bank credit lines	$ 0	$ 400,000

Leases - Supplemental cash flow information (Details)
$ in Thousands

12 Months Ended

Dec. 28, 2019

USD ($)

Cash paid for amounts included in the measurement of lease liabilities

Operating cash flows for operating leases

$ 79,699

Operating cash flows for finance leases

Financing cash flows for finance leases

1,413

Right-of-use assets obtained in exchange for lease obligations:

Operating leases

297,800

^[1]

Finance leases

$ 2,940

[1]	Includes leases that commenced during the year ended December 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

Commitments and Contingencies - Other Commitments (Details) $ in Thousands	12 Months Ended
	Dec. 28, 2019 USD ($)
Employment, consulting and non-compete agreements [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
2019	$ 16,800
2020	6,300
2021	4,500
2022	900
2023	900
Life-time consulting agreement [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
Current compensation paid under lifetime consulting agreement	400
Amount of increase effective every fifth year on lifetime consulting agreement	$ 25

Comprehensive Income

12 Months Ended

Dec. 28, 2019

Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]

Comprehensive Income

Note 9 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity.

The following table summarizes our Accumulated other comprehensive income, net of applicable taxes as of:

			December 28,		December 29,		December 30,
			2019		2018		2017
Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(20,338)	$	(18,595)	$	(5,564)

Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	(531)	$	(426)	$	539

Attributable to Henry Schein, Inc.:
	Foreign currency translation adjustment		$	(143,172)	$	(234,799)	$	(112,439)
	Unrealized loss from foreign currency hedging activities			(4,032)		(156)		(782)
	Unrealized investment gain (loss )			6		(6)		(3)
	Pension adjustment loss			(20,175)		(13,810)		(16,843)
		Accumulated other comprehensive loss	$	(167,373)	$	(248,771)	$	(130,067)

Total Accumulated other comprehensive loss			$	(188,242)	$	(267,792)	$	(135,092)

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	December 28,		December 29,		December 30,
	2019		2018		2017
Net income	$	719,138	$	562,126	$	459,293

Foreign currency translation gain (loss)		(4,070)		(136,356)		191,886
Tax effect		-		-		-
Foreign currency translation gain (loss)		(4,070)		(136,356)		191,886

Unrealized gain (loss) from foreign currency hedging activities		(4,911)		1,022		(1,515)
Tax effect		1,035		(396)		786
Unrealized gain (loss) from foreign currency hedging activities		(3,876)		626		(729)

Unrealized investment gain (loss)		14		(3)		(4)
Tax effect		(2)		-		1
Unrealized investment gain (loss)		12		(3)		(3)

Pension adjustment gain (loss)		(7,730)		4,212		4,247
Tax effect		1,806		(1,179)		(314)
Pension adjustment gain (loss)		(5,924)		3,033		3,933

Comprehensive income	$	705,280	$	429,426	$	654,380

Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the years ended December 28, 2019, December 29, 2018 and December 30, 2017 was impacted by changes in foreign currency exchange rates of the Euro, Brazilian Real, British Pound and Australian Dollar.The following table summarizes our total comprehensive income, net of applicable taxes as follows:

		December 28,		December 29,		December 30,
		2019		2018		2017
Comprehensive income attributable to
	Henry Schein, Inc.	$	682,724	$	417,177	$	593,273
Comprehensive income attributable to
	noncontrolling interests		9,827		3,432		1,443
Comprehensive income attributable to
	Redeemable noncontrolling interests		12,729		8,817		59,664
Comprehensive income		$	705,280	$	429,426	$	654,380

Business Acquisitions and Divestitures (Narrative) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 29, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Business Acquisition [Line Items]
Net sales	$ 2,668,941,000	$ 2,508,767,000	$ 2,447,827,000	$ 2,360,268,000	$ 2,472,556,000	$ 2,355,565,000	$ 2,316,032,000	$ 2,273,450,000	$ 9,985,803,000	$ 9,417,603,000	$ 8,883,438,000
Business acquisition allocated, goodwill	2,462,495,000				2,081,029,000				2,462,495,000	2,081,029,000	1,553,582,000
Net gain (loss) on sale of equity investments	(186,769,000)	$ 0	$ 0	$ 0					(186,769,000)	0	17,636,000
Income Tax Expense (Benefit)									159,515,000	107,432,000	308,975,000
Equity in earnings of affiliates									(17,900,000)	(21,037,000)	(15,293,000)
Business Acquisition, Transaction Costs	4,500,000				7,300,000				4,500,000	7,300,000	5,300,000
Proceeds from sale of equity investment									307,251,000	1,000,000	34,048,000
Hu-Friedy Mfg. Co., LLC [Member]
Business Acquisition [Line Items]
Net gain (loss) on sale of equity investments	(250,200,000)
Income Tax Expense (Benefit)	63,400,000
Equity in earnings of affiliates									(6,000,000.0)	(10,400,000)	(6,400,000)
E4D Technologies [Member]
Business Acquisition [Line Items]
Net gain (loss) on sale of equity investments											17,600,000
Income Tax Expense (Benefit)											0
Animal Health [Member]
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	23,600,000				38,900,000				23,600,000	38,900,000
Technology and Value-Added Services [Member]
Business Acquisition [Line Items]
Net sales									515,085,000	408,439,000	337,633,000
Business acquisition allocated, goodwill	$ 985,776,000				$ 647,617,000				985,776,000	647,617,000	121,902,000
Income Tax Expense (Benefit)									30,134,000	$ 53,772,000	$ 37,055,000
Internet Brands Inc [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Increase from Business Combination									$ 550,900,000
Internet Brands Inc [Member] \| Henry Schein One, LLC. [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	26.00%								26.00%
Noncontrolling interest, ownership percentage increase, second through fifth anniversary									7.60%
Noncontrolling interest, ownership percentage maximum additional increase, contingency									1.60%
Henry Schein One, LLC. [Member] \| Technology and Value-Added Services [Member]
Business Acquisition [Line Items]
Business acquisition allocated, goodwill	$ 533,900,000								$ 533,900,000
Henry Schein Inc, and certain minority holders, if applicable [Member] \| Henry Schein One, LLC. [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	74.00%								74.00%
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Increase from Business Combination									$ 72,500,000
Net assets	$ 19,700,000								19,700,000
Business acquisition allocated, goodwill	395,300,000								395,300,000
Intangible Assets	$ 310,400,000								310,400,000
Payments to Acquire Businesses									$ 652,900,000

Related Party Transactions (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Covetrus, Inc. [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	In connection with the completion of the Animal Health Spin-off during our fiscal year 2019, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.
Related Party Transaction, Expenses from Transactions with Related Party	$ 17.5
Revenue from Related Parties	81.3
Due from Related Parties	4.5
Due to Related Parties	$ 0.1
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $31.0 million annually for the use of their intellectual property.
Related Party Transaction, Amounts of Transaction	$ 31.0	$ 15.5
Related Party Transaction, Due from (to) Related Party	9.4	2.4
Internet Brands Inc [Member] \| Scenario, Plan [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 31.0
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Related Party Transaction, Amounts of Transaction	$ 87.7	27.0	$ 23.4
Related Party Transaction, Purchases from Related Party	18.1	10.8	$ 8.8
Due from Related Parties	60.7	61.4
Due to Related Parties	$ 5.3	$ 1.0

Segment and Geographic Data (Tables)

12 Months Ended

Dec. 28, 2019

Segment Reporting [Abstract]

Business segment information


			Years Ended
			December 28,		December 29,		December 30,
			2019		2018		2017
Net Sales:
	Health care distribution ⁽¹⁾
		Dental	$	6,415,865	$	6,347,998	$	6,047,811
		Medical		2,973,586		2,661,166		2,497,994
		Total health care distribution		9,389,451		9,009,164		8,545,805
	Technology and value-added services ⁽²⁾			515,085		408,439		337,633
		Total excluding Corporate TSA revenues		9,904,536		9,417,603		8,883,438
	Corporate TSA revenues ⁽³⁾			81,267		-		-
		Total	$	9,985,803	$	9,417,603	$	8,883,438

(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
	generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
	and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and
	other services.

(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection
	with the Animal Health Spin-off, which we expect to continue through August 2020.

			Years ended
			December 28,		December 29,		December 30,
			2019		2018		2017
Operating Income:
	Health care distribution		$	591,404	$	490,988	$	561,888
	Technology and value-added services			126,857		109,631		107,873
		Total	$	718,261	$	600,619	$	669,761

Income before taxes and equity in earnings of affiliates:
	Health care distribution		$	553,181	$	429,429	$	526,255
	Technology and value-added services			127,126		107,407		103,539
		Total	$	680,307	$	536,836	$	629,794

Depreciation and Amortization:
	Health care distribution		$	146,960	$	122,767	$	116,260
	Technology and value-added services			37,982		20,863		17,595
		Total	$	184,942	$	143,630	$	133,855

Income Tax Expense:
	Health care distribution		$	129,381	$	53,660	$	271,920
	Technology and value-added services			30,134		53,772		37,055
		Total	$	159,515	$	107,432	$	308,975

Interest Income:
	Health care distribution		$	15,352	$	15,106	$	12,236
	Technology and value-added services			405		385		202
		Total	$	15,757	$	15,491	$	12,438

Interest Expense:
	Health care distribution		$	50,666	$	76,006	$	51,039
	Technology and value-added services			126		10		27
		Total	$	50,792	$	76,016	$	51,066

Purchases of Fixed Assets:
	Health care distribution		$	69,095	$	68,577	$	59,865
	Technology and value-added services			7,124		2,706		2,539
		Total	$	76,219	$	71,283	$	62,404

			As of
			December 28,		December 29,		December 30,
			2019		2018		2017
Total Assets:
	Health care distribution		$	5,822,057	$	5,289,348	$	5,336,320
	Technology and value-added services			1,329,044		994,506		334,977
	Discontinued operations			-		2,216,673		2,192,698
		Total	$	7,151,101	$	8,500,527	$	7,863,995

Operations by geographic area

		2019				2018				2017
		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets
United States		$	6,876,194	$	2,400,733	$	6,411,558	$	1,855,788	$	6,039,613	$	1,208,351
Other			3,109,609		1,195,947		3,006,045		915,493		2,843,825		1,072,849
	Consolidated total	$	9,985,803	$	3,596,680	$	9,417,603	$	2,771,281	$	8,883,438	$	2,281,200

Income Taxes - Income before Taxes and Equity in Earnings of Affiliates and Provisions for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Income before equity method investments, income taxes and loss on sale of equity investment [Abstract]
Domestic	$ 507,003	$ 405,289	$ 526,586
Foreign	173,304	131,547	103,208
Income from continuing operations before taxes and equity in earnings of affiliates and noncontrolling interest	$ 680,307	$ 536,836	$ 629,794

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Dec. 28, 2019	Dec. 29, 2018
Top customer concentration risk [Member] \| Sales revenue, net [Member] \| Any single customer [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	1.00%	1.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Top ten health care distribution suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	31.00%	31.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Single largest supplier [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	6.00%	6.00%

Goodwill and Other Intangibles, Net

12 Months Ended

Dec. 28, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangibles, Net

Note 4 – Goodwill and Other Intangibles, Net

The changes in the carrying amount of goodwill for the years ended December 28, 2019 and December 29, 2018 were as follows:

			Health Care Distribution		Technology and Value-Added Services		Total
Balance as of December 30, 2017			$	1,431,680	$	121,902	$	1,553,582
	Adjustments to goodwill:
		Acquisitions		38,848		530,064		568,912
		Foreign currency translation		(37,116)		(4,349)		(41,465)
Balance as of December 29, 2018				1,433,412		647,617		2,081,029
	Adjustments to goodwill:
		Acquisitions		50,276		338,352		388,628
		Foreign currency translation		(6,969)		(193)		(7,162)
Balance as of December 28, 2019			$	1,476,719	$	985,776	$	2,462,495

Other intangible assets consisted of the following:

	December 28, 2019						December 29, 2018
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Non-compete agreements	$	34,553	$	(9,327)	$	25,226	$	34,667	$	(6,834)	$	27,833
Trademarks / trade names - definite lived		99,314		(44,134)		55,180		72,462		(36,165)		36,297
Customer relationships and lists		715,630		(274,330)		441,300		479,542		(216,007)		263,535
Product Development		85,211		(42,326)		42,885		73,294		(34,689)		38,605
Other		26,237		(17,950)		8,287		34,620		(24,859)		9,761
Total	$	960,945	$	(388,067)	$	572,878	$	694,585	$	(318,554)	$	376,031

Non-compete agreements represent amounts paid primarily to key employees and prior owners of acquired businesses, as well as certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete period, which generally commences upon termination of employment or separation from us. The weighted-average non-compete period for agreements currently being amortized was approximately 4.9 years as of December 28, 2019.

Trademarks, trade names, customer lists and customer relationships were established through business acquisitions. Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-average period of approximately 8.0 years as of December 28, 2019. Customer relationships and customer lists are definite-lived intangible assets that are amortized on a straight-line basis over a weighted-average period of approximately 10.0 years as of December 28, 2019. Product development is a definite-lived intangible asset that is amortized on a straight-line basis over a weighted-average period of approximately 8.6 years as of December 28, 2019.

Amortization expense related to definite-lived intangible assets for the years ended December 28, 2019, December 29, 2018 and December 30, 2017 was $108.3 million, $75.3 million and $70.3 million. The annual amortization expense expected to be recorded for existing intangibles assets for the years 2020 through 2024 is $102.7 million, $95.6 million, $81.4 million, $73.7 million and $59.3 million.

Income Taxes - Provisions for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Current income tax expense:
U.S. Federal	$ 93,418	$ 71,854	$ 247,254
State and local	28,150	22,533	19,489
Foreign	42,004	38,433	41,043
Total current	163,572	132,820	307,786
Deferred income tax expense (benefit):
U.S. Federal	5,633	206	12,927
State and local	1,597	(1,622)	1,621
Foreign	(11,287)	(23,972)	(13,359)
Total deferred	(4,057)	(25,388)	1,189
Total income tax provision	$ 159,515	$ 107,432	$ 308,975

Comprehensive Income - Total Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income (loss) attributable to Henry Schein, Inc.	$ 682,724	$ 417,177	$ 593,273
Comprehensive income (loss) attributable to noncontrolling interests	9,827	3,432	1,443
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	12,729	8,817	59,664
Comprehensive income (loss)	$ 705,280	$ 429,426	$ 654,380

Plans of Restructuring

12 Months Ended

Dec. 28, 2019

Restructuring and Related Activities [Abstract]

Plans of Restructuring

Note 12 – Plans of Restructuring

On July 9, 2018, we committed to an initiative to rationalize our operations and provide expense efficiencies. These actions allowed us to execute on our plan to reduce our cost structure and fund new initiatives that drive growth under our 2018 to 2020 strategic plan. This initiative has resulted in the elimination of approximately 4% of our workforce and the closing of certain facilities.

During the years ended December 28, 2019 and December 29, 2018, we recorded restructuring charges of $14.7 million and $54.4 million, respectively. The costs associated with these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

On November 20, 2019, we committed to the contemplated initiative, intended to mitigate stranded costs associated with the Animal Health Spin-off as well as to rationalize operations and provide expense efficiencies. These activities are expected to be completed by the end of 2020. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. We will disclose this information after we determine such estimates or range of estimates.

The following table shows the amounts expensed and paid for restructuring costs that were incurred during our 2019, 2018 and 2017 fiscal years and the remaining accrued balance of restructuring costs as of December 28, 2019, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet:


			Facility
	Severance		Closing
	Costs		Costs		Other		Total
Balance, December 31, 2016	$	20,447	$	2,130	$	73	$	22,650
Provision		-		-		-		-
Payments and other adjustments		(17,360)		(815)		(49)		(18,224)
Balance, December 30, 2017	$	3,087	$	1,315	$	24	$	4,426
Provision		50,197		3,153		1,017		54,367
Payments and other adjustments		(23,320)		(2,865)		(883)		(27,068)
Balance, December 29, 2018	$	29,964	$	1,603	$	158	$	31,725
Provision		13,741		937		27		14,705
Payments and other adjustments		(30,794)		(1,714)		(112)		(32,620)
Balance, December 28, 2019	$	12,911	$	826	$	73	$	13,810

The following table shows, by reportable segment, the amounts expensed and paid for restructuring costs that were incurred during our 2019, 2018 and 2017 fiscal years and the remaining accrued balance of restructuring costs as of December 28, 2019:

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 31, 2016	$	22,505	$	145	$	22,650
Provision		-		-		-
Payments and other adjustments		(18,079)		(145)		(18,224)
Balance, December 30, 2017	$	4,426	$	-	$	4,426
Provision		50,824		3,543		54,367
Payments and other adjustments		(24,959)		(2,109)		(27,068)
Balance, December 29, 2018	$	30,291	$	1,434	$	31,725
Provision		13,935		770		14,705
Payments and other adjustments		(30,853)		(1,767)		(32,620)
Balance, December 28, 2019	$	13,373	$	437	$	13,810

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax provision at federal statutory rate	$ 142,865	$ 112,735	$ 220,427
State income tax provision, net of federal income tax effect	16,539	15,872	10,320
Foreign income tax provision	(4,580)	(2,558)	(19,486)
Pass through noncontrolling interest	(3,931)	(2,700)	(1,465)
Valuation allowance	(79)	2,017	1,629
Unrecognized tax benefits and audit settlements	3,671	2,126	4,196
Interest expense related to loans	(5,498)	(11,700)	(18,492)
Excess tax benefits related to stock compensation	(86)	(1,008)	(16,964)
Transition tax on deemed repatriation of foreign earnings	0	(10,000)	140,000
Revaluation of deferred tax assets and liabilities	0	(1,676)	2,953
Tax on global intangible low-taxed income ("GILTI")	3,917	7,599	0
Tax benefit related to legal entity reorganization outside the U.S.	0	(13,852)	0
Tax charge related to reorganization of legal entities related to forming Henry Schein One	0	3,914	0
Tax charge related to reorganization of legal entities completed in preparation for the Animal Health spin-off	(1,333)	3,135	0
Other	8,030	3,528	(14,143)
Total income tax provision	$ 159,515	$ 107,432	$ 308,975

Investments and Other

12 Months Ended

Dec. 28, 2019

Investments And Other [Abstract]

Investments and Other

Note 5 – Investments and Other

Investments and other consisted of the following:

		December 28,		December 29,
		2019		2018
Investment in unconsolidated affiliates		$	164,659	$	260,954
Non-current deferred foreign, state and local income taxes			23,625		12,196
Notes receivable (1)			43,544		66,047
Capitalized costs for internally generated software for resale			42,445		37,659
Distribution rights and exclusivity agreements, net of amortization			4		582
Security deposits			534		-
Acquisition-related indemnification			38,464		28,283
Other long-term assets			14,644		14,646
	Total	$	327,919	$	420,367

(1)	Long-term notes receivable carry interest rates ranging from 1.0% to 11.5% and are due in varying installments through
	February 01, 2025.

Amortization expense related to other long-term assets for the years ended December 28, 2019, December 29, 2018 and December 30, 2017 was $12.3 million, $10.2 million and $8.8 million.

Leases - Future minimum lease payments under non-cancelable operating leases and capital leases (Details) $ in Thousands	Dec. 28, 2019 USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2019	$ 62,535
2020	47,686
2021	34,633
2022	25,626
2023	19,560
Thereafter	62,918
Total minimum lease payments	252,958
Capital Leases, Future Minimum Payments Due [Abstract]
2019	976
2020	801
2021	501
2022	305
2023	283
Thereafter	1,430
Total minimum lease payments	4,296
Less imputed interest	(352)
Total present value of minimum lease payments	$ 3,944

Discontinued Operations - Summarized financial information for our discontinued operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017	Feb. 07, 2019	Dec. 31, 2016
Summarized financial information for our discontinued operations
Costs of goods sold	$ 6,894,917	$ 6,506,856	$ 6,136,776
Selling, general and administrative	2,357,920	2,217,273	2,071,576
Income (loss) from discontinued operations	(6,323)	111,685	140,817
Net (income) loss attributable to noncontrolling interests	366	(6,521)	(27,690)
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	(5,957)	105,164	113,127
Assets transferred
Total current assets of discontinued operations	0	1,083,014
Operating lease right-of-use assets	231,662	0
Investments and other	327,919	420,367
Total long-term assets of discontinued operations	0	1,133,659
Liabilities transferred
Current maturities of long-term debt	109,849	8,280
Operating lease liabilities	65,349	0
Accrued expenses:
Total current liabilities of discontinued operations	0	577,607
Long-term debt	622,908	980,344
Operating lease liabilities	176,267	0
Total long-term liabilities of discontinued operations	0	62,453
Redeemable noncontrolling interests	287,258	219,724	465,585		$ 285,567
Henry Schein Animal Health Business [Member]
Summarized financial information for our discontinued operations
Net sales	319,522	3,784,392	3,578,105
Costs of goods sold	260,097	3,100,055	2,925,664
Gross Profit	59,425	684,337	652,441
Selling, general and administrative	68,919	531,905	462,835
Operating income (loss)	(9,494)	152,432	189,606
Income tax expense (benefit)	(2,181)	48,060	53,532
Income (loss) from discontinued operations	(6,323)	111,685	140,817
Net (income) loss attributable to noncontrolling interests	366	(6,521)	(27,690)
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	(5,957)	105,164	$ 113,127
Assets transferred
Cash and cash equivalents		23,324		$ 6,815
Accounts receivable, net		434,935		432,812
Inventories, net		555,230		536,637
Prepaid expenses and other		69,525		120,546
Total current assets of discontinued operations		1,083,014		1,096,810
Property and equipment, net		68,177		69,790
Operating lease right-of-use assets		0		57,012
Goodwill		739,266		742,931
Other intangibles, net		208,213		205,793
Investments and other		118,003		120,518
Total long-term assets of discontinued operations		1,133,659		1,196,044
Total assets of discontinued operations		2,216,673		2,292,854
Liabilities transferred
Accounts payable		441,453		316,162
Current maturities of long-term debt		675		657
Operating lease liabilities		0		18,951
Accrued expenses:
Payroll and related		36,888		36,847
Taxes		17,552		24,060
Other		81,039		80,400
Total current liabilities of discontinued operations		577,607		477,077
Long-term debt		23,529		1,176,105
Deferred income taxes		4,352		17,019
Operating lease liabilities		0		38,668
Other liabilities		34,572		29,209
Total long-term liabilities of discontinued operations		62,453		1,261,001
Total liabilities of discontinued operations		640,060		1,738,078
Redeemable noncontrolling interests	$ 0	$ 92,432		$ 28,270

Leases (Tables)

12 Months Ended

Dec. 28, 2019

Leases

Components of lease expense, supplemental cash flow, and supplemental balance sheet information

		Year Ended
		December 28,
		2019
Operating lease cost⁽¹⁾		$	88,246
Finance lease cost:
	Amortization of right-of-use assets	$	1,154
	Interest on lease liabilities		131
Total finance lease cost		$	1,285

(1)	Includes variable lease expenses.

Maturities of operating lease liabilities

Supplemental balance sheet information related to leases is as follows:
		December 28,
		2019
Operating Leases:
Operating lease right-of-use assets		$	231,662

Current operating lease liabilities			65,349
Non-current operating lease liabilities			176,267
	Total operating lease liabilities	$	241,616

Finance Leases:
Property and equipment, at cost		$	10,268
Accumulated depreciation			(4,581)
Property and equipment, net of accumulated depreciation		$	5,687

Current maturities of long-term debt		$	1,736
Long-term debt			3,658
	Total finance lease liabilities	$	5,394

Weighted Average Remaining Lease Term in Years:
	Operating leases		5.5
	Finance leases		5.0

Weighted Average Discount Rate:
	Operating leases		3.4	%
	Finance leases		2.2	%

Maturities of finance lease liabilities

Supplemental cash flow information related to leases is as follows:
		December 28,
		2019
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	79,699
	Operating cash flows for finance leases		99
	Financing cash flows for finance leases		1,413
Right-of-use assets obtained in exchange for lease obligations:
	Operating leases ⁽¹⁾	$	297,800
	Finance leases		2,940

(1)	Includes leases that commenced during the year ended December 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

Future minimum lease payments of operating leases under the previous lease accounting standard

Maturities of lease liabilities are as follows:
		December 28,
		2019
		Operating		Finance
		Leases		Leases
2020	$	70,986	$	1,853
2021		56,557		1,529
2022		40,601		646
2023		27,021		304
2024		18,944		283
Thereafter		51,762		1,117
Total future lease payments		265,871		5,732
Less: imputed interest		(24,255)		(338)
Total	$	241,616	$	5,394

Future minimum lease payments of finance leases under the previous lease accounting standard

		Operating		Capital
		Leases		Leases
2019	$	62,535	$	976
2020		47,686		801
2021		34,633		501
2022		25,626		305
2023		19,560		283
Thereafter		62,918		1,430
Total minimum lease payments	$	252,958		4,296
Less: imputed interest (Capital leases only)				(352)
Total present value of minimum lease payments			$	3,944

Commitments and Contingencies - Unrecorded Unconditional Purchase Obligation (Details) $ in Thousands	Dec. 28, 2019 USD ($)
Unrecorded Unconditional Purchase Obligation [Abstract]
2019	$ 403,241
2020	208,200
2021	110,800
2022	0
2023	0
Thereafter	0
Total minimum inventory purchase commitment payments	$ 722,241

Discontinued Operations (Tables)

12 Months Ended

Dec. 28, 2019

Discontinued Operations

Summarized financial information for discontinued operations

Summarized financial information for our discontinued operations is as follows:

	Year Ended
	December 28,		December 29,			December 30,
	2019		2018			2017

Net sales	$	319,522	$	3,784,392	$	3,578,105
Cost of goods sold		260,097		3,100,055		2,925,664
Gross profit		59,425		684,337		652,441
Selling, general and administrative		68,919		531,905		462,835
Operating income (loss)		(9,494)		152,432		189,606
Income tax expense (benefit)		(2,181)		48,060		53,532
Income (loss) from discontinued operations		(6,323)		111,685		140,817
Net (income) loss attributable to noncontrolling interests		366		(6,521)		(27,690)
Net income (loss) from discontinued operations
attributable to Henry Schein, Inc.		(5,957)		105,164		113,127

The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019 and December 29, 2018.

			February 7,		December 29,
			2019		2018


Cash and cash equivalents			$	6,815	$	23,324
Accounts receivable, net				432,812		434,935
Inventories, net				536,637		555,230
Prepaid expenses and other				120,546		69,525
		Total current assets of discontinued operations		1,096,810		1,083,014
Property and equipment, net				69,790		68,177
Operating lease right-of-use asset, net				57,012		-
Goodwill				742,931		739,266
Other intangibles, net				205,793		208,213
Investments and other				120,518		118,003
		Total long-term assets of discontinued operations		1,196,044		1,133,659
Total assets of discontinued operations			$	2,292,854	$	2,216,673

Accounts payable			$	316,162	$	441,453
Current maturities of long-term debt				657		675
Operating lease liabilities				18,951		-
Accrued expenses:
	Payroll and related			36,847		36,888
	Taxes			24,060		17,552
	Other			80,400		81,039
		Total current liabilities of discontinued operations		477,077		577,607
Long-term debt				1,176,105		23,529
Deferred income taxes				17,019		4,352
Operating lease liabilities				38,668		-
Other liabilities				29,209		34,572
		Total long-term liabilities of discontinued operations		1,261,001		62,453
Total liabilities of discontinued operations			$	1,738,078	$	640,060
Redeemable noncontrolling interests			$	28,270	$	92,432

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Commitments and Contingencies - Litigation (Details)	3 Months Ended								12 Months Ended
Commitments and Contingencies - Litigation (Details)	Dec. 28, 2019 USD ($) claims	Sep. 28, 2019 USD ($)	Jun. 29, 2019 USD ($)	Mar. 30, 2019 USD ($)	Dec. 29, 2018 USD ($)	Sep. 29, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 28, 2019 USD ($) claims	Dec. 29, 2018 USD ($)	Dec. 30, 2017 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Litigation settlements					$ 0	$ 38,488,000	$ 0	$ 0	$ 0	$ 38,488,000	$ 5,325,000
Net sales	$ 2,668,941,000	$ 2,508,767,000	$ 2,447,827,000	$ 2,360,268,000	$ 2,472,556,000	$ 2,355,565,000	$ 2,316,032,000	$ 2,273,450,000	$ 9,985,803,000	$ 9,417,603,000	$ 8,883,438,000
Loss Contingency, Management's Assessment and Process									As of December 28, 2019, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.
Archer and White Sales, Inc. v. collectively, the Danaher Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									August 31, 2012
Loss Contingency, Name of Defendant									Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”)
Loss Contingency, Name of Plaintiff									Archer and White Sales, Inc.
Loss Contingency, Allegations									Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights.
Archer filed amended complaint adding Patterson and Benco as Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									August 1, 2017
Loss Contingency, Name of Defendant									adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants
Loss Contingency, Name of Plaintiff									Archer
Loss Contingency, Allegations									alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer.
Archer filed second amended complaint under seal [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									October 30, 2017
Loss Contingency, Name of Plaintiff									Archer
Loss Contingency, Allegations									add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.
IQ Dental Supply, Inc V. Henry Schein, Inc. Patterson Companies, Inc. [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									August 17, 2017
Loss Contingency, Name of Defendant									Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company
Loss Contingency, Name of Plaintiff									IQ Dental Supply, Inc.
Loss Contingency, Allegations									Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental (“SourceOne”).
United States Federal Trade Commission [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									February 12, 2018
Loss Contingency, Name of Defendant									against Benco Dental Supply Co., Henry Schein, Inc. and Patterson Companies, Inc.
Loss Contingency, Name of Plaintiff									United States Federal Trade Commission
Loss Contingency, Allegations									The FTC alleged, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement, to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners.
Salkowitz v. Henry Schein, Inc. et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									March 7, 2018
Loss Contingency, Name of Defendant									against Henry Schein, Inc., Stanley M. Bergman and Steven Paladino
Loss Contingency, Name of Plaintiff									Joseph Salkowitz, individually and on behalf of all others similarly situated
Loss Contingency, Allegations									The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, including matters relating to the issues in the In re Dental Supplies Antitrust Litigation which Henry Schein settled and which the court dismissed in June 2019, as described in our prior filings with the SEC, and the FTC action described above, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities.
Marion Diagnostic Center, LLC, et al. v. Becton, Dickinson, and Co., et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									May 3, 2018
Loss Contingency, Name of Defendant									Becton, Dickinson, and Co., et al., Case No. 3:18-cv-010509, was filed in the U.S. District Court for the Southern District of Illinois against Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton Distributor Co-Conspirators.
Loss Contingency, Name of Plaintiff									Marion Diagnostic Center, LLC, et al.
Loss Contingency, Allegations									The complaint alleges that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels.
The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									May 29, 2018
Loss Contingency, Name of Defendant									Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants.
Loss Contingency, Name of Plaintiff									The County of Summit, Ohio et al.
Loss Contingency, Allegations									Summit County alleges that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation dedicated to making grants to programs within Summit County focused on (i) educating the community on alternative pain management treatment techniques and/or avoiding addiction; ‎(ii) supporting research into alternative pain management techniques and protocols; (iii) enabling professionals to obtain the necessary certification for a Medication Assisted Treatment (MAT) Waiver; and (iv) advancing programs and services to Summit County to deliver results and solutions to the opiate and addiction crises. Henry Schein paid $250,000 of Summit County’s expenses.
Donation amount to Pain Management Education Foundation									$ 1,000,000
Litigation Settlement, Amount Awarded to Other Party									$ 250,000
Actions consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Name of Defendant									Henry Schein and/or one or more of its affiliated companies
Loss Contingency, Allegations									allege claims similar to those alleged in the County of Summit Action.
Actions consolidated in the MultiDistrict Litigation [Member] \| Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	125								125
Maximum sales of opioids in North America during the year, percentage									0.10%
Actions consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Net sales									$ 9,400,000,000
R. Lawrence Hatchett, M.D. against Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									January 29, 2019
Loss Contingency, Name of Defendant									Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators
Loss Contingency, Name of Plaintiff									R. Lawrence Hatchett, M.D.
Loss Contingency, Allegations									The complaint alleges that the alleged conspiracy overcharged Illinois dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the class.
City of Hollywood Police Officers Retirement System V. Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									September 30, 2019
Loss Contingency, Name of Defendant									Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola
Loss Contingency, Name of Plaintiff									City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated
Loss Contingency, Allegations									. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger.
Frank Finazzo against various present and former directors and officers of Henry Schein [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									November 15, 2019
Loss Contingency, Name of Defendant									The named defendants in the action are Stanley M. Bergman, Steven Paladino, Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph L. Herring, Donald J. Kabat, Kurt Kuehn, Philip A. Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews, Mark E. Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares, and Louis W. Sullivan, with Henry Schein named as a nominal defendant.
Loss Contingency, Name of Plaintiff									Frank Finazzo
Loss Contingency, Allegations									The Complaint asserts claims under the federal securities laws and state law relating to the allegations in the antitrust actions, the In re Henry Schein, Inc. Securities Litigation, and the City of Hollywood securities class action described above.

Plans of Restructuring (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 29, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax	$ (1,059)	$ (802)	$ 11,925	$ 4,641	$ 34,644	$ 8,551	$ 8,497	$ 2,675	$ 14,705	$ 54,367	$ 0
Employee severance pay and benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax									13,741	50,197	0
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax									$ 937	$ 3,153	$ 0
Strategic Plan, 2018 to 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent									4.00%

Employee Benefit Plans - Other Employee Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Management [Member] \| Deferred compensation bonus and commission plan [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation plan fair market value amount charged (credited) to operations	$ 8.3	$ (2.3)	$ 5.0
Qualified 401K plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ (36.8)	(35.8)	(33.5)
Qualified 401K plan [Member] \| Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum matching contributions as a percentage of participants' contributions (as a percent)	100.00%
Maximum participants' contributions as a percentage of their base compensation (as a percent)	7.00%
Allowable maximum percentage of contributions allocated to Henry Schein Stock Fund (as a percent)	20.00%
Supplemental executive retirement plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ (2.1)	$ (0.4)	$ (0.6)

Employee Benefit Plans - Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax share-based compensation expense	$ 44,900,000	$ 32,600,000	$ 36,800,000
After-tax share-based compensation expense	34,400,000	25,300,000	$ 20,600,000
Excess tax benefits	0	$ 0
Liability for cash settlement stock-based compensation awards	$ 600,000
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)	$ 56.83	$ 71.38	$ 85.43
Total unrecognized compensation cost related to non-vested awards	$ 84,800,000
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	2 years
Total cash received as a result of stock options exercises	$ 34,000	$ 3,076,000	$ 5,266,000
Stock option exercises tax benefits	0	$ 0
Long-term Incentive Program [Member] \| Henry Schein Animal Health Business [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total cash received as a result of stock options exercises	$ 0.0
Long-term Incentive Program [Member] \| Restricted stock/units [Member] \| Henry Schein Animal Health Business [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	1.2633
Decrease in price per share	$ (1.2633)

Comprehensive Income (Tables)

12 Months Ended

Dec. 28, 2019

Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]

Accumulated other comprehensive income, net of applicable taxes

			December 28,		December 29,		December 30,
			2019		2018		2017
Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(20,338)	$	(18,595)	$	(5,564)

Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	(531)	$	(426)	$	539

Attributable to Henry Schein, Inc.:
	Foreign currency translation adjustment		$	(143,172)	$	(234,799)	$	(112,439)
	Unrealized loss from foreign currency hedging activities			(4,032)		(156)		(782)
	Unrealized investment gain (loss )			6		(6)		(3)
	Pension adjustment loss			(20,175)		(13,810)		(16,843)
		Accumulated other comprehensive loss	$	(167,373)	$	(248,771)	$	(130,067)

Total Accumulated other comprehensive loss			$	(188,242)	$	(267,792)	$	(135,092)

Components of comprehensive income, net of applicable taxes

	December 28,		December 29,		December 30,
	2019		2018		2017
Net income	$	719,138	$	562,126	$	459,293

Foreign currency translation gain (loss)		(4,070)		(136,356)		191,886
Tax effect		-		-		-
Foreign currency translation gain (loss)		(4,070)		(136,356)		191,886

Unrealized gain (loss) from foreign currency hedging activities		(4,911)		1,022		(1,515)
Tax effect		1,035		(396)		786
Unrealized gain (loss) from foreign currency hedging activities		(3,876)		626		(729)

Unrealized investment gain (loss)		14		(3)		(4)
Tax effect		(2)		-		1
Unrealized investment gain (loss)		12		(3)		(3)

Pension adjustment gain (loss)		(7,730)		4,212		4,247
Tax effect		1,806		(1,179)		(314)
Pension adjustment gain (loss)		(5,924)		3,033		3,933

Comprehensive income	$	705,280	$	429,426	$	654,380

Total comprehensive income, net of applicable taxes

		December 28,		December 29,		December 30,
		2019		2018		2017
Comprehensive income attributable to
	Henry Schein, Inc.	$	682,724	$	417,177	$	593,273
Comprehensive income attributable to
	noncontrolling interests		9,827		3,432		1,443
Comprehensive income attributable to
	Redeemable noncontrolling interests		12,729		8,817		59,664
Comprehensive income		$	705,280	$	429,426	$	654,380

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 28, 2019	Feb. 14, 2020	Jun. 29, 2019
Cover Page
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-28
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 28, 2019
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN INC
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Public Float			$ 10,236,712,000
Entity Common Stock, Shares Outstanding		143,390,505
Entity Voluntary Filers	No
Documents Incorporated by Reference	Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the fiscal year (December 28, 2019) are incorporated by reference in Part III hereof.

Supplemental Cash Flow Information

12 Months Ended

Dec. 28, 2019

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Note 22 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

	Years ended
	December 28,		December 29,		December 30,
	2019		2018		2017
Interest	$	54,685	$	69,371	$	46,985
Income taxes		177,277		236,479		214,135

There was approximately $0.0 million, $0.0 million and $0.3 million of debt assumed as a part of the acquisitions for the years ended December 28, 2019, December 29, 2018 and December 30, 2017, respectively.

For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, we had $(4.9) million, $1.0 million and $(1.5) million of non-cash net unrealized gains (losses) related to foreign currency hedging activities, respectively. During the year ended December 30, 2017, as part of business acquisitions, we increased our ownership interests in subsidiaries through non-cash transactions of $16.8 million.

During the third quarter of 2018, we formed Henry Schein One, LLC with Internet Brands through a non-cash transaction resulting in approximately $390.3 million of noncontrolling interest representing Internet Brands’ current 26% minority interest and $160.6 million of deferred additional ownership interests of Internet Brands in Henry Schein One, representing up to an additional 9.2% ownership interests at December 28, 2019, a portion of which is contingent upon the achievement of certain operating targets (See Note 11).

Business Acquisitions and Divestitures

12 Months Ended

Dec. 28, 2019

Business Acquisitions and Divestitures [Abstract]

Business Acquisitions and Divestitures

Note 11 – Business Acquisitions and Divestitures

The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.

We completed acquisitions during the year ended December 28, 2019, which were immaterial to our financial statements individually. In the aggregate, these transactions resulted in consideration of $652.9 million in 2019 related to business combinations, for net assets amounting to $19.7 million. As of December 28, 2019, we had recorded $310.4 million identifiable intangibles, $395.3 million of goodwill and $72.5 million of non-controlling interest, related to these acquisitions.

Henry Schein One, LLC

On July 1, 2018, we closed on a joint venture with Internet Brands, a provider of web presence and online marketing software, to create a newly formed entity, Henry Schein One, LLC. The joint venture includes Henry Schein Practice Solutions products and services, as well as Henry Schein’s international dental practice management systems and the dental businesses of Internet Brands. We own 74% of the joint venture and Internet Brands owns the remaining 26% noncontrolling interest, which is accounted for within stockholders’ equity. In addition, Internet Brands received a freestanding and separately exercisable right to put their noncontrolling interest to Henry Schein, Inc. for fair value following the fifth anniversary of the effective date of the formation of the joint venture. Beginning with the second anniversary of the effective date of the formation of the joint venture, Henry Schein One will issue a fixed number of additional interests to Internet Brands through the fifth anniversary of the effective date, thereby increasing Internet Brands’ ownership by approximately 7.6%. Internet Brands will also be entitled to receive a fixed number of additional interests, in the aggregate up to approximately 1.6% of the joint venture’s ownership, if certain operating targets are met by the joint venture in its fourth, fifth and sixth operating years. These additional shares are considered contingent consideration that are accounted for within stockholders’ equity; however these shares will not be allocated any net income of Henry Schein One until the shares vest or are earned by Internet Brands. A Monte Carlo simulation was utilized to value the additional contingent interests that are subject to operating targets. Key assumptions that were applied to derive the fair value of the contingent interests include an assumed equity value of Henry Schein One, LLC at its inception date, a risk-free interest rate based on U.S. treasury yields, an assumed future dividend yield, a risk-adjusted discount rate applied to projected future cash flows, an assumed equity volatility based on historical stock price returns of a group of guideline companies, and an estimated correlation of annual cash flow returns to equity returns. As a result of the transaction with Internet Brands, we recorded $550.9 million of noncontrolling interest within stockholders’ equity as of December 28, 2019.

Senior management from Henry Schein and Internet Brands serve on the board of Henry Schein One. The goodwill recorded as part of the acquisition primarily reflects the value of future synergies. We allocated all of the goodwill to our Technology and value-added services reporting segment. As of December 28, 2019, the goodwill associated with this transaction is $533.9 million. None of the goodwill recognized is deductible for income tax purposes, and as such, no deferred taxes have been recorded related to goodwill.

Concurrent with the formation of Henry Schein One, LLC, we entered into a separate agreement with Internet Brands whereby (1) beginning July 1, 2023, Internet Brands will have the right to require Henry Schein to purchase all or a portion of Internet Brands ownership interests in Henry Schein One, LLC for fair market value, and (2) beginning July 1, 2028, or earlier if certain events occur, Henry Schein will have the right to require Internet Brands to sell all or a portion of its ownership interests in Henry Schein One, LLC to Henry Schein for fair market value.

Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.

Divestitures of Investments

During the fourth quarter of 2019, we sold an equity investment in Hu-Friedy Mfg. Co., LLC, a manufacturer of dental instruments and infection prevention solutions. Our investment was non-controlling, we were not involved in running the business and had no representation on the board of directors. During the fourth quarter of 2019, we also sold certain other equity investments. In the aggregate, the sales of these investments resulted in a pre-tax gain of approximately $250.2 million, net of taxes of approximately $63.4 million. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, we recognized approximately $6.0 million, $10.4 million and $6.4 million of equity in earnings from these affiliates.

During 2017 we sold our equity ownership in E4D Technologies resulting in a loss of approximately $17.6 million. There was no tax benefit recognized related to this loss.

Acquisition Costs

During the years ended December 28, 2019, December 29, 2018 and December 30, 2017 we incurred $4.5 million, $7.3 million and $5.3 million in acquisition costs from continuing operations.

In February 2019, we completed the Animal Health Spin-off. During the years ended December 28, 2019 and December 29, 2018, we incurred $23.6 million and $38.9 million in transaction costs associated with this transaction. We expect to incur additional spin-off related transaction costs during 2020 related to required tax and other matters. All transaction costs related to the Animal Health Spin-off have been included in results from discontinued operations.

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 219,724	$ 465,585	$ 285,567
Decrease in redeemable noncontrolling interests due to redemptions	(2,270)	(287,767)	(22,294)
Increase in redeemable noncontrolling interests due to business acquisitions	74,865	4,655	72,291
Net income attributable to redeemable noncontrolling interests	14,838	15,327	24,513
Dividends declared	(10,264)	(8,206)	(7,680)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(2,335)	(11,330)	4,530
Change in fair value of redeemable securities	(7,300)	41,460	108,658
Balance, end of period	$ 287,258	$ 219,724	$ 465,585

Employee Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017	Dec. 31, 2016
Employee and director stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	3	155	353
Granted (in shares)	0	0	0
Exercised (in shares)	(3)	(152)	(198)
Forfeited (in shares)	0	0	0
Outstanding at end of period (in shares)	0	3	155
Ending balance, options exercisable (in shares)	0	3	155
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 17.22	$ 29.65	$ 28.59
Granted (in dollars per share)		0	0
Exercised (in dollars per share)		29.81	27.76
Forfeited (in dollars per share)		0	0
Outstanding at end of period (in dollars per share)		17.22	29.65
Ending balance, options exercisable (in dollars per share)		$ 17.22	29.65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock option outstanding aggregate intrinsic value as of period end	$ 0	$ 121		$ 6,256
Stock option exercisable aggregate intrinsic value as of period end	$ 0	$ 121		$ 6,256
Restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of restricted stock that vested during the year (in dollars per share)	$ 64.31	$ 76.48	$ 83.16
Time-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares)	1,513
Granted (in shares)	452
Vested (in shares)	(339)
Forfeited (in shares)	(208)
Ending balance outstanding (in shares)	1,418	1,513
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 57.94
Granted (in dollars per share)	59.56
Vested (in dollars per share)	55.62
Forfeited (in dollars per share)	60.35
Ending balance outstanding (in dollars per share)	58.72	$ 57.94
Intrinsic value (in dollars per share)	$ 66.58
Performance-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period over which earnings per share performance is measured against specified targets (in years)	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares)	1,163
Granted (in shares)	642
Vested (in shares)	(189)
Forfeited (in shares)	(157)
Ending balance outstanding (in shares)	1,459	1,163
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 40.26
Granted (in dollars per share)	59.72
Vested (in dollars per share)	66.41
Forfeited (in dollars per share)	61.33
Ending balance outstanding (in dollars per share)	61.41	$ 40.26
Intrinsic value (in dollars per share)	66.58
Long-term Incentive Program [Member] \| Employee and director stock options [Member] \| Henry Schein Animal Health Business [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	13.63
Granted (in dollars per share)	0
Exercised (in dollars per share)	13.63
Forfeited (in dollars per share)	0
Outstanding at end of period (in dollars per share)	0	$ 13.63
Ending balance, options exercisable (in dollars per share)	$ 0
2013 Stock Incentive Plan, as amended [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	65,242
Shares available to be granted (in shares)	6,113
2013 Stock Incentive Plan, as amended [Member] \| Time-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	4 years
2013 Stock Incentive Plan, as amended [Member] \| Performance-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	1,892
Shares available to be granted (in shares)	294
2015 Non-Employee Director Stock Incentive Plan [Member] \| Time-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	12 months

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018
Current assets:
Accounts receivable, reserves (in dollars)	$ 60,002	$ 53,121
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	143,353,459	151,401,668

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Statement of Stockholders' Equity [Abstract]
Unrealized gain (loss) from foreign currency hedging activities, (tax benefit) tax	$ 1,035,000	$ (396,000)	$ 786,000
Unrealized investment gain (loss), tax benefit (tax)	2,000	0	(1,000)
Pension adjustment gain (loss), tax benefit (tax)	(1,806,000)	(1,179,000)	314,000
Stock issued upon exercise of stock options, tax benefit	0	0
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests		21,848,000	52,203,000
Foreign currency translation (gain) loss	2,335,000	11,330,000	(4,530,000)
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests	14,838,000
Foreign currency translation (gain) loss	2,335,000	$ 13,031,000	$ (7,461,000)
Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests	(366,000)
Foreign currency translation (gain) loss	$ (592,000)

Debt (Tables)

12 Months Ended

Dec. 28, 2019

Debt [Abstract]

Bank credit lines

	December 28,		December 29,
	2019		2018
Revolving credit agreement	$	-	$	175,000
Other short-term bank credit lines		23,975		376,458
Committed loan associated with Animal Health spin-off		-		400,000
Total	$	23,975	$	951,458

Schedule of long-term debt

		December 28,		December 29,
		2019		2018
Private placement facilities		$	621,274	$	628,189
U.S. trade accounts receivable securitization			100,000		350,000
Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2024 at interest rates
	ranging from 2.56% to 10.5% at December 28, 2019 and
	ranging from 2.61% to 4.17% at December 29, 2018		6,089		6,491
Finance lease obligations (see Note 7)			5,394		3,944
Total			732,757		988,624
Less current maturities			(109,849)		(8,280)
	Total long-term debt	$	622,908	$	980,344

Private placement facilities


	Amount of
Date of	Borrowing		Borrowing
Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012 (1)		21,429	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
June 2, 2014		100,000	3.19		June 2, 2021
June 16, 2017		100,000	3.42		June 16, 2027
September 15, 2017		100,000	3.52		September 15, 2029
January 2, 2018		100,000	3.32		January 2, 2028
Less: Deferred debt issuance costs		(155)
	$	621,274

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

Schedule of long-term debt maturities

2020		$	109,849
2021			108,842
2022			110,504
2023			1,529
2024			101,112
Thereafter			300,921
	Total	$	732,757

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Derivatives and Hedging Activities

12 Months Ended

Dec. 28, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives and Hedging Activities

Note 16 – Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.

During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in Accumulated other comprehensive loss within our Consolidated Balance Sheet. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our Consolidated Statement of Income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023, is €200 million. During December 28, 2019 we recognized approximately $0.6 million of interest savings as a result of this net investment hedge.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 28, 2019
Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. See Note 8 for accounting treatment of Redeemable noncontrolling interests. Certain prior period amounts have been reclassified to conform to the current period presentation. We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements. For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. For the years ended December 28, 2019 and December 29, 2018, trade accounts receivable that can only be used to settle obligations of this VIE were $127 million and $422 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were $100 million and $350 million, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fiscal Year	Fiscal Year We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of December. The years ended December 28, 2019, December 29, 2018 and December 30, 2017 consisted of 52 weeks.
Revenue Recognition	Revenue Recognition On December 31, 2017, we adopted Accounting Standards Codification (“ASC”) 606 (“Topic 606”) using the modified retrospective method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning after December 30, 2017 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods. Our revenue recognition accounting policies applied prior to adoption of Topic 606 are outlined in the financial statements in our Annual Report on Form 10-K for the year ended December 30, 2017. The disclosures included herein reflect our accounting policies under Topic 606. Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following: • identify the contract(s) with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when, or as, the entity satisfies a performance obligation. We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment. Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with ASC 460 “Guarantees”. Revenue derived from the sale of software products is recognized when products are shipped to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract. Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. There are no cases where revenue is deferred due to a lack of a standalone selling price. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions See Note 17 for additional disclosures of disaggregated net sales and Note 18 for disclosures of net sales by segment and geographic data. Contract Balances Contract balances represent amounts presented in our consolidated balance sheet when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Accounts Receivable Accounts receivable are generally recognized when heath care distribution and technology and value-added services revenues are recognized. The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability. Contract Assets Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in Investments and other within our consolidated balance sheet. Current and non-current contract asset balances as of December 28, 2019 and December 29, 2018 were not material. Contract Liabilities Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in Accrued expenses: Other and the non-current contract liabilities are included in Other liabilities within our consolidated balance sheet. At December 29, 2018, the current portion of contract liabilities of $65.3 million was reported in Accrued expenses: Other, and $5.0 million related to non-current contract liabilities were reported in Other liabilities. During the year ended December 28, 2019, we recognized substantially all of the current contract liability amounts that were previously deferred at December 29, 2018. At December 28, 2019, the current and non-current portion of contract liabilities were $70.8 million and $6.2 million, respectively. Deferred Commissions Sales commissions earned by our sales force that relate to long term arrangements are capitalized as costs to obtain a contract when the costs incurred are incremental and are expected to be recovered. Deferred sales commissions are amortized over the estimated customer relationship period. We apply the practical expedient related to the capitalization of incremental costs of obtaining a contract, and recognize such costs as an expense when incurred if the amortization period of the assets that we would have recognized is one year or less. Our deferred commission balances as of December 28, 2019 and December 29, 2018 were not material. Sales Returns Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any goods or services that we expect to be returned. Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $73.8 million, $70.6 million and $65.0 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017. Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $29.5 million and $41.1 million, primarily related to payments for inventory, were classified as accounts payable as of December 28, 2019 and December 29, 2018.
Inventories and Reserves	Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.
Advertising and Promotional Costs	Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $25.2 million, $12.9 million and $0.8 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method (see Note 3 - Property and Equipment, Net for estimated useful lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized.
Income Taxes	Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Our accounting for the Tax Cuts and Jobs Act, enacted on December 22, 2017, is further discussed in Note 14–Income Taxes. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries. On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35% to 21%, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. In the fourth quarter of 2017, we recorded provisional amounts for any items that could be reasonably estimated at the time. This included the one-time transition tax that we estimated to be $140.0 million and a net deferred tax expense of $3.0 million attributable to the revaluation of deferred taxes due to the lower enacted federal income tax rate of 21%. We completed our analysis in the year ended December 29, 2018 and recorded a net $10.0 million reduction to the one-time transition tax and an additional $1.7 million net deferred tax benefit from the revaluation of deferred taxes to reflect the new tax rate. Absent the effects of the transition tax and the revaluation of deferred tax assets and liabilities, our effective tax rate for the year ended December 30, 2017 would have been 26.4% as compared to our actual effective tax rate of 49.1%. Within our consolidated balance sheets, transition tax of $9.9 million was included in “Accrued taxes” for 2019 and 2018, and $94.9 million and $104.2 million were included in “Other liabilities” for 2019 and 2018, respectively. The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income (“GILTI”), states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. We recorded a current tax expense for the GILTI provision of $7.6 million and $3.9 million for 2018 and 2019, respectively.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings.
Risk Management and Derivative Financial Instruments	Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item. Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings.
Acquisitions	Acquisitions We account for business acquisitions and combinations under the acquisition method of accounting, where the net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rates; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, there were no material adjustments recorded in our consolidated statement of income relating to changes in subsequent adjustments or estimated contingent purchase price liabilities.
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. Noncontrolling Interests Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.
Goodwill and Other Indefinite-Lived Intangibles Assets	Goodwill Goodwill is not amortized, but are subject to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: health care distribution (global dental and medical) and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017 we tested goodwill for impairment using a quantitative analysis consisting of a two-step approach. The first step of our quantitative analysis consists of a comparison of the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If step one results in the carrying value of the reporting unit exceeding the fair value of such reporting unit, we would then proceed to step two which would require us to calculate the amount of impairment loss, if any, that we would record for such reporting unit. The calculation of the impairment loss in step two would be equivalent to the reporting unit’s carrying value of goodwill less the implied fair value of such goodwill. Our use of a discounted cash flow methodology includes estimates of future revenue based upon budget projections and growth rates, which take into account estimated inflation rates. We also develop estimates for future levels of gross profits and operating profits and projected capital expenditures. Our methodology also includes the use of estimated discount rates based upon industry and competitor analysis as well as other factors. The estimates that we use in our discounted cash flow methodology involve many assumptions by management that are based upon future growth projections. Some factors we consider important that could trigger an interim impairment review include: • significant underperformance relative to expected historical or projected future operating results; • significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or • significant negative industry or economic trends. If we determine through the impairment review process that goodwill is impaired, we record an impairment charge in our consolidated statements of income. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, the results of our goodwill analysis did not result in any impairments.
Long-Lived Assets	Long-Lived Assets Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
Cost of Sales	Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $72.3 million, $69.6 million and $67.5 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.
Comprehensive Income	Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).
Leases	Leases We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases finance leases are included in “Selling, general and administrative” and “Interest expense”, respectively within our Consolidated Statement of Income. Leases with a lease term of 12 months or less are not capitalized. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Short-term Leases	Leases with a lease term of 12 months or less are not capitalized.
Separation of Lease and Nonlease Components	We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Accounting Pronouncements Adopted	Recently Issued Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. This ASU is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance of this ASU is effective. Based upon the level and makeup of our financial asset portfolio, past loan loss activity and current known activity regarding our outstanding loans, we do not expect that this ASU will have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 will require us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. ASU 2017-04 is required to be implemented on a prospective basis for fiscal years beginning after December 15, 2019. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements

Redeemable Noncontrolling Interests

12 Months Ended

Dec. 28, 2019

Temporary Equity Disclosure [Abstract]

Redeemable Noncontrolling Interests

Note 8 – Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the Redeemable noncontrolling interests for the years ended December 28, 2019, December 29, 2018 and December 30, 2017 are presented in the following table:

		December 28,		December 29,		December 30,
		2019		2018		2017
Balance, beginning of period		$	219,724	$	465,585	$	285,567
Decrease in redeemable noncontrolling interests due to
	redemptions		(2,270)		(287,767)		(22,294)
Increase in redeemable noncontrolling interests due to
	business acquisitions		74,865		4,655		72,291
Net income attributable to redeemable noncontrolling interests			14,838		15,327		24,513
Dividends declared			(10,264)		(8,206)		(7,680)
Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		(2,335)		(11,330)		4,530
Change in fair value of redeemable securities			(7,300)		41,460		108,658
Balance, end of period		$	287,258	$	219,724	$	465,585

Revenue from Contracts with Customers

12 Months Ended

Dec. 28, 2019

Revenue from Contracts with Customers [Abstract]

Revenue from Contract with Customer

Note 17 – Revenue from Contracts with Customers

Revenue (Net sales) is recognized in accordance with the policies discussed in Note 1 – Significant Accounting Policies.

Disaggregation of Net sales

The following table disaggregates our Net sales by reportable segment and geographic area:

				Year Ended
				December 28, 2019
				North America		International		Global
Revenues:
	Health care distribution
		Dental		$	3,911,746		2,504,119		6,415,865
		Medical			2,894,137		79,449		2,973,586
			Total health care distribution		6,805,883		2,583,568		9,389,451
	Technology and value-added services				445,317		69,768		515,085
	Total excluding Corporate TSA revenues⁽¹⁾				7,251,200		2,653,336		9,904,536
	Corporate TSA revenues⁽¹⁾				4,098		77,169		81,267
		Total revenues		$	7,255,298	$	2,730,505	$	9,985,803

				Year Ended
				December 29, 2018
				North America		International		Global
Revenues:
	Health care distribution
		Dental		$	3,866,171		2,481,827		6,347,998
		Medical			2,581,696		79,470		2,661,166
			Total health care distribution		6,447,867		2,561,297		9,009,164
	Technology and value-added services				344,168		64,271		408,439
	Total excluding Corporate TSA revenues⁽¹⁾				6,792,035		2,625,568		9,417,603
	Corporate TSA revenues⁽¹⁾				-		-		-
		Total revenues		$	6,792,035	$	2,625,568	$	9,417,603

(1)

Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement

entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

Leases

12 Months Ended

Dec. 28, 2019

Leases

Leases

Note 7 – Leases

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of less than one year to 16 years, some of which may include options to extend the leases for up to 10 years. The components of lease expense were as follows:

		Year Ended
		December 28,
		2019
Operating lease cost⁽¹⁾		$	88,246
Finance lease cost:
	Amortization of right-of-use assets	$	1,154
	Interest on lease liabilities		131
Total finance lease cost		$	1,285

(1)	Includes variable lease expenses.

Supplemental balance sheet information related to leases is as follows:
		December 28,
		2019
Operating Leases:
Operating lease right-of-use assets		$	231,662

Current operating lease liabilities			65,349
Non-current operating lease liabilities			176,267
	Total operating lease liabilities	$	241,616

Finance Leases:
Property and equipment, at cost		$	10,268
Accumulated depreciation			(4,581)
Property and equipment, net of accumulated depreciation		$	5,687

Current maturities of long-term debt		$	1,736
Long-term debt			3,658
	Total finance lease liabilities	$	5,394

Weighted Average Remaining Lease Term in Years:
	Operating leases		5.5
	Finance leases		5.0

Weighted Average Discount Rate:
	Operating leases		3.4	%
	Finance leases		2.2	%

Supplemental cash flow information related to leases is as follows:
		December 28,
		2019
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	79,699
	Operating cash flows for finance leases		99
	Financing cash flows for finance leases		1,413
Right-of-use assets obtained in exchange for lease obligations:
	Operating leases ⁽¹⁾	$	297,800
	Finance leases		2,940

(1)	Includes leases that commenced during the year ended December 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

As of December 28, 2019 we have additional operating leases with total lease payments of $9.0 million for buildings and vehicles that have not yet commenced. These operating leases will commence during 2020 with lease terms of two to 10 years.

As previously disclosed in our December 29, 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments under non-cancelable operating leases and capital leases as of December 29, 2018 were as follows (in thousands):

		Operating		Capital
		Leases		Leases
2019	$	62,535	$	976
2020		47,686		801
2021		34,633		501
2022		25,626		305
2023		19,560		283
Thereafter		62,918		1,430
Total minimum lease payments	$	252,958		4,296
Less: imputed interest (Capital leases only)				(352)
Total present value of minimum lease payments			$	3,944

Earnings Per Share

12 Months Ended

Dec. 28, 2019

Earnings Per Share [Abstract]

Earnings Per Share

Note 13 – Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

		Years Ended
		December 28,	December 29,	December 30,
		2019	2018	2017
Basic		147,817	152,656	156,787
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,440	1,051	1,421
	Diluted	149,257	153,707	158,208

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Income Statement [Abstract]
Net sales	$ 9,985,803	$ 9,417,603	$ 8,883,438
Cost of sales	6,894,917	6,506,856	6,136,776
Gross profit	3,090,886	2,910,747	2,746,662
Operating expenses:
Selling, general and administrative	2,357,920	2,217,273	2,071,576
Litigation settlements	0	38,488	5,325
Restructuring costs	14,705	54,367	0
Operating income	718,261	600,619	669,761
Other income (expense):
Interest income	15,757	15,491	12,438
Interest expense	(50,792)	(76,016)	(51,066)
Other, net	(2,919)	(3,258)	(1,339)
Income from continuing operations before taxes and equity in earnings of affiliates and noncontrolling interest	680,307	536,836	629,794
Income taxes	(159,515)	(107,432)	(308,975)
Equity in earnings of affiliates	17,900	21,037	15,293
Net gain (loss) on sale of equity investments	186,769	0	(17,636)
Income from continuing operations	725,461	450,441	318,476
Income (loss) from discontinued operations	(6,323)	111,685	140,817
Net income	719,138	562,126	459,293
Less: Net income attributable to noncontrolling interests	(24,770)	(19,724)	(25,304)
Less: Net (income) loss attributable to noncontrolling interests from discontinued operations	(366)	6,521	27,690
Net income attributable to Henry Schein, Inc.	694,734	535,881	406,299
Continuing Operations	700,691	430,717	293,172
Discontinued operations	(5,957)	105,164	113,127
Net income attributable to Henry Schein, Inc.	$ 694,734	$ 535,881	$ 406,299
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 4.74	$ 2.82	$ 1.87
Diluted (in dollars per share)	4.69	2.80	1.85
Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	(0.04)	0.69	0.72
Diluted (in dollars per share)	(0.04)	0.68	0.72
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	4.70	3.51	2.59
Diluted (in dollars per share)	$ 4.65	$ 3.49	$ 2.57
Weighted-average common shares outstanding:
Basic (in shares)	147,817	152,656	156,787
Diluted (in shares)	149,257	153,707	158,208

Goodwill and Other Intangibles, Net - Other Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Other intangible assets cost	$ 960,945	$ 694,585
Other intangible assets net	572,878	376,031
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated amortization	(388,067)	(318,554)
Non-compete agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	34,553	34,667
Accumulated amortization	(9,327)	(6,834)
Net	$ 25,226	27,833
Non-compete agreements [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	4 years 10 months 24 days
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 99,314	72,462
Accumulated amortization	(44,134)	(36,165)
Net	$ 55,180	36,297
Trademarks and tradenames [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	8 years
Customer relationships and lists [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 715,630	479,542
Accumulated amortization	(274,330)	(216,007)
Net	$ 441,300	263,535
Customer relationships and lists [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	10 years
Product development [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 85,211	73,294
Accumulated amortization	(42,326)	(34,689)
Net	$ 42,885	38,605
Product development [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	8 years 7 months 6 days
Other intangibles assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 26,237	34,620
Accumulated amortization	(17,950)	(24,859)
Net	$ 8,287	$ 9,761

Leases - Present value of lease liabilities (Details) - USD ($) $ in Thousands	Dec. 28, 2019	Dec. 29, 2018
Present value of lease liabilities - Operating Leases
Total future lease payments	$ 265,871
Less imputed interest	(24,255)
Total operating lease liabilities	241,616
Present value of lease liabilities - Finance Leases
Total future lease payments	5,732
Less imputed interest	(338)
Total finance lease liabilities	$ 5,394	$ 3,944

Leases - Narrative (Details) $ in Millions	12 Months Ended
Leases - Narrative (Details) $ in Millions	Dec. 28, 2019 USD ($)
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Description	We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment.
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Lessee, Operating Lease, Lease Not yet Commenced, Description	buildings and vehicles
Operating lease assets, Lease not yet commenced	$ 9.0
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	1 year
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	2 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	16 years
Lessee, Operating Lease, Option to Extend	may include options to extend the leases for up to 10 years
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	10 years

Fair Value Measurements

12 Months Ended

Dec. 28, 2019

Fair Value Measurements [Abstract]

Fair Value Measurements

Note 10 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The hierarchy for determining that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets.

Debt

The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy as of December 28, 2019 and December 29, 2018 was estimated at $756.7 million and $1,940.1 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy.

Redeemable noncontrolling interests

The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. The details of the changes in Redeemable noncontrolling interests are presented in Note 8.

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 28, 2019 and December 29, 2018:

			December 28, 2019
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	567	$	-	$	567
		Total assets	$	-	$	567	$	-	$	567

Liabilities:
	Derivative contracts		$	-	$	5,795	$	-	$	5,795
		Total liabilities	$	-	$	5,795	$	-	$	5,795

Redeemable noncontrolling interests			$	-	$	-	$	287,258	$	287,258

			December 29, 2018
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	12,533	$	-	$	12,533
		Total assets	$	-	$	12,533	$	-	$	12,533

Liabilities:
	Derivative contracts		$	-	$	1,708	$	-	$	1,708
		Total liabilities	$	-	$	1,708	$	-	$	1,708

Redeemable noncontrolling interests			$	-	$	-	$	219,724	$	219,724

Investments and Other (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 28, 2019

Dec. 29, 2018

Dec. 30, 2017

Investments And Other [Abstract]

Investments in unconsolidated affiliates

$ 164,659

$ 260,954

Non-current deferred foreign, state and local income taxes

23,625

12,196

Notes receivable

^[1]

43,544

66,047

Capitalized costs for internally generated software for resale

42,445

37,659

Distribution rights and exclusivity agreements, net of amortization

582

Security deposits

534

Acquisition related indemnification

38,464

28,283

Other long-term assets

14,644

14,646

Total

327,919

420,367

Amortization of other long-term assets

$ 12,300

$ 10,200

$ 8,800

[1]	Long-term notes receivable carry interest rates ranging from 1.0% to 11.5% and are due in varying installments through February 01, 2025.

Employee Benefit Plans

12 Months Ended

Dec. 28, 2019

Employee Benefit Plans

Note 19 – Employee Benefit Plans

Stock-based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $44.9 million ($34.4 million after-tax), $32.6 million ($25.3 million after-tax) and $36.8 million ($20.6 million after-tax) for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013 Stock Incentive Plan, as amended, and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and restricted stock/units. Since March 2009, equity-based awards have been granted solely in the form of restricted stock/units, with the exception of providing stock options to employees pursuant to certain pre-existing contractual obligations. As of December 28, 2019, there were 65,242 shares authorized and 6,113 shares available to be granted under the 2013 Stock Incentive Plan and 1,892 shares authorized and 294 shares available to be granted under the 2015 Non-Employee Director Stock Incentive Plan.

Grants of restricted stock/units are stock-based awards granted to recipients with specified vesting provisions. In the case of restricted stock, common stock is delivered on the date of grant, subject to vesting conditions. In the case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting conditions. We issue restricted stock/units that vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily 12-month cliff vesting) and restricted stock/units that vest based on our achieving

specified performance measurements and the recipient’s continued service over time (primarily three-year cliff vesting).

With respect to time-based restricted stock/units, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock/units, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock/units based on our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted stock/units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, changes in accounting principles or in applicable laws or regulations, certain foreign exchange fluctuations, certain litigation related costs, and material changes in income tax rates. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

As a result of the Separation, the number of our unvested equity-based awards from previous grants to our remaining employees under our Long-term Incentive Program was increased in accordance with the provisions in the Plans. This was based on a factor of approximately 1.2633, corresponding with a decrease in our price per share.

We record deferred income tax assets for awards that will result in future deductions on our income tax returns based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction.

During the first quarter of 2017, we adopted the provisions of ASU 2016-09 which requires that all excess tax benefits and tax deficiencies resulting from the difference between the deduction for tax purposes and the stock-based compensation cost recognized for financial reporting purposes be included as a component of income tax expense as of January 1, 2017. Prior to the implementation of ASU 2016-09, excess tax benefits were recorded as a component of Additional paid-in capital and tax deficiencies were recognized either as an offset to accumulated excess tax benefits or in the income statement if there were no accumulated excess tax benefits.

Stock-based compensation grants for the three years ended December 28, 2019 consisted of restricted stock/unit grants. Certain stock-based compensation granted may require us to settle in the form of a cash payment. During the year ended December 28, 2019, we recorded a liability of $0.6 million relating to the grant date fair value of stock-based compensation to be settled in cash. The weighted-average grant date fair value of stock-based awards granted before forfeitures was $56.83, $71.38 and $85.43 per share during the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Total unrecognized compensation cost related to non-vested awards as of December 28, 2019 was $84.8 million, which is expected to be recognized over a weighted-average period of approximately 2.0 years.

A summary of the stock option activity under the Plans is presented below:

	Years Ended
	December 28,			December 29,			December 30,
	2019			2018			2017

		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at beginning of year	3	$	13.63	155	$	29.65	353	$	28.59
Granted	-		-	-		-	-		-
Exercised	(3)		13.63	(152)		29.81	(198)		27.76
Forfeited	-		-	-		-	-		-
Outstanding at end of year	-	$	-	3	$	17.22	155	$	29.65

Options exercisable at end of year	-	$	-	3	$	17.22	155	$	29.65

The following table represents the intrinsic values of:

	As of
	December 28,		December 29,		December 30,
	2019		2018		2017
Stock options outstanding	$	-	$	121	$	6,256
Stock options exercisable		-		121		6,256

The total cash received as a result of stock option exercises for the years ended December 28, 2019, December 29, 2018 and December 30, 2017 was approximately $0.0 million, $3.1 million and $5.3 million. In connection with these exercises, we did not realize any tax benefits for the years ended December 28, 2019, December 29, 2018 and December 30, 2017. We settle employee stock option exercises with newly issued common shares.The total intrinsic value per share of restricted stock/units that vested was $64.31, $76.48 and $83.16 during the years ended December 28, 2019, December 29, 2018 and December 30, 2017. The following table summarizes the status of our non-vested restricted stock/units for the year ended December 28, 2019:


	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,513	$	57.94
Granted	452		59.56
Vested	(339)		55.62
Forfeited	(208)		60.35
Outstanding at end of period	1,418	$	58.72	$	66.58
	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,163	$	40.26
Granted	642		59.72
Vested	(189)		66.41
Forfeited	(157)		61.33
Outstanding at end of period	1,459	$	61.41	$	66.58

401(k) Plans

We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our Board of Directors, matching contributions to these plans generally do not exceed 100% of the participants’ contributions up to 7% of their base compensation, subject to applicable legal limits. Matching contributions consist of cash and were allocated entirely to the participants’ investment elections on file, subject to a 20% allocation limit to the Henry Schein Stock Fund. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are used to reduce our matching contributions and offset administrative expenses of the 401(k) plans.

Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to choose from various investment fund options. Matching contributions and administrative expenses related to these plans charged to operations during the years ended December 28, 2019, December 29, 2018 and December 30, 2017 amounted to $36.8 million, $35.8 million and $33.5 million, respectively.

Supplemental Executive Retirement Plan

We offer an unfunded, non-qualified supplemental executive retirement plan to eligible employees. This plan generally covers officers and certain highly-compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to base compensation for the portion of the year in which such employees are not eligible to make pre-tax contributions to the 401(k) plan. The amounts charged (credited) to operations during the years ended December 28, 2019, December 29, 2018 and December 30, 2017 amounted to $2.1 million, $(0.4 )million and $0.6 million, respectively.

Deferred Compensation Plan

During 2011, we began to offer a deferred compensation plan to a select group of management or highly compensated employees of the Company and certain subsidiaries. This plan allows for the elective deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged (credited) to operations during the years ended December 28, 2019, December 29, 2018 and December 30, 2017 were approximately $8.3 million, $(2.3) million and $5.0 million, respectively.

Significant Accounting Policies

12 Months Ended

Dec. 28, 2019

Significant Accounting Policies [Abstract]

Significant Accounting Policies

Note 1 –Significant Accounting Policies

Nature of Operations

We distribute health care products and services primarily to office-based health care practitioners with operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom.

Principles of Consolidation

Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. See Note 8 for accounting treatment of Redeemable noncontrolling interests. Certain prior period amounts have been reclassified to conform to the current period presentation.

We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. For the years ended December 28, 2019 and December 29, 2018, trade accounts receivable that can only be used to settle obligations of this VIE were $127 million and $422 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were $100 million and $350 million, respectively.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fiscal Year

We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of December. The years ended December 28, 2019, December 29, 2018 and December 30, 2017 consisted of 52 weeks.

Revenue Recognition

On December 31, 2017, we adopted Accounting Standards Codification (“ASC”) 606 (“Topic 606”) using the modified retrospective method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning after December 30, 2017 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods.

Our revenue recognition accounting policies applied prior to adoption of Topic 606 are outlined in the financial statements in our Annual Report on Form 10-K for the year ended December 30, 2017. The disclosures included herein reflect our accounting policies under Topic 606.

Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following:

• identify the contract(s) with a customer;

• identify the performance obligations in the contract;

• determine the transaction price;

• allocate the transaction price to the performance obligations in the contract; and

• recognize revenue when, or as, the entity satisfies a performance obligation.

We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized.

Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment.

Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with ASC 460 “Guarantees”.

Revenue derived from the sale of software products is recognized when products are shipped to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer.

Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract.

Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.

Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. There are no cases where revenue is deferred due to a lack of a standalone selling price. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions

See Note 17 for additional disclosures of disaggregated net sales and Note 18 for disclosures of net sales by segment and geographic data.

Contract Balances

Contract balances represent amounts presented in our consolidated balance sheet when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities.

Accounts Receivable

Accounts receivable are generally recognized when heath care distribution and technology and value-added services revenues are recognized. The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability.

Contract Assets

Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in Investments and other within our consolidated balance sheet. Current and non-current contract asset balances as of December 28, 2019 and December 29, 2018 were not material.

Contract Liabilities

Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in Accrued expenses: Other and the non-current contract liabilities are included in Other liabilities within our consolidated balance sheet. At December 29, 2018, the current portion of contract liabilities of $65.3 million was reported in Accrued expenses: Other, and $5.0 million related to non-current contract liabilities were reported in Other liabilities. During the year ended December 28, 2019, we recognized substantially all of the current contract liability amounts that were

previously deferred at December 29, 2018. At December 28, 2019, the current and non-current portion of contract liabilities were $70.8 million and $6.2 million, respectively.

Deferred Commissions

Sales commissions earned by our sales force that relate to long term arrangements are capitalized as costs to obtain a contract when the costs incurred are incremental and are expected to be recovered. Deferred sales commissions are amortized over the estimated customer relationship period. We apply the practical expedient related to the capitalization of incremental costs of obtaining a contract, and recognize such costs as an expense when incurred if the amortization period of the assets that we would have recognized is one year or less. Our deferred commission balances as of December 28, 2019 and December 29, 2018 were not material.

Sales Returns

Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any goods or services that we expect to be returned.

Cash and Cash Equivalents

We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $29.5 million and $41.1 million, primarily related to payments for inventory, were classified as accounts payable as of December 28, 2019 and December 29, 2018.

Inventories and Reserves

Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.

Direct Shipping and Handling Costs

Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $73.8 million, $70.6 million and $65.0 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Advertising and Promotional Costs

We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $25.2 million, $12.9 million and $0.8 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Supplier Rebates

Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method (see Note 3 - Property and Equipment, Net for estimated useful lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term.

Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized.

Income Taxes

We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Our accounting for the Tax Cuts and Jobs Act, enacted on December 22, 2017, is further discussed in Note 14–Income Taxes. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.

Foreign Currency Translation and Transactions

The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings.

Risk Management and Derivative Financial Instruments

We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges.

Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item.

Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated.

Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes.

For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings.

Acquisitions

We account for business acquisitions and combinations under the acquisition method of accounting, where the net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rates; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations. For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, there were no material adjustments recorded in our consolidated statement of income relating to changes in subsequent adjustments or estimated contingent purchase price liabilities.

Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting

period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Noncontrolling Interests

Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.

Goodwill

Goodwill is not amortized, but are subject to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: health care distribution (global dental and medical) and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis.

For the years ended December 28, 2019, December 29, 2018 and December 30, 2017 we tested goodwill for impairment using a quantitative analysis consisting of a two-step approach. The first step of our quantitative analysis consists of a comparison of the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If step one results in the carrying value of the reporting unit exceeding the fair value of such reporting unit, we would then proceed to step two which would require us to calculate the amount of impairment loss, if any, that we would record for such reporting unit. The calculation of the impairment loss in step two would be equivalent to the reporting unit’s carrying value of goodwill less the implied fair value of such goodwill.

Our use of a discounted cash flow methodology includes estimates of future revenue based upon budget projections and growth rates, which take into account estimated inflation rates. We also develop estimates for future levels of gross profits and operating profits and projected capital expenditures. Our methodology also includes the use of estimated discount rates based upon industry and competitor analysis as well as other factors. The estimates that we use in our discounted cash flow methodology involve many assumptions by management that are based upon future growth projections.

Some factors we consider important that could trigger an interim impairment review include:

• significant underperformance relative to expected historical or projected future operating results;

• significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or

• significant negative industry or economic trends.

If we determine through the impairment review process that goodwill is impaired, we record an impairment charge in our consolidated statements of income.

For the years ended December 28, 2019, December 29, 2018 and December 30, 2017, the results of our goodwill analysis did not result in any impairments.

Long-Lived Assets

Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets.

Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

Cost of Sales

The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs.

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $72.3 million, $69.6 million and $67.5 million for the years ended December 28, 2019, December 29, 2018 and December 30, 2017.

Comprehensive Income

Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).

Leases

We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases finance leases are included in “Selling, general and

administrative” and “Interest expense”, respectively within our Consolidated Statement of Income. Leases with a lease term of 12 months or less are not capitalized.

We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.

Recently Issued Accounting Standards

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. This ASU is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance of this ASU is effective. Based upon the level and makeup of our financial asset portfolio, past loan loss activity and current known activity regarding our outstanding loans, we do not expect that this ASU will have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 will require us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. ASU 2017-04 is required to be implemented on a prospective basis for fiscal years beginning after December 15, 2019. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance For Doubtful Accounts And Other [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 53,121	$ 46,261	$ 33,150
Charged to statement of income	12,612	14,384	7,915
Charged to other accounts	134	(1,158)	11,341
Deductions	(5,865)	(6,366)	(6,145)
Balance at end of period	$ 60,002	$ 53,121	$ 46,261

Property and Equipment, Net

12 Months Ended

Dec. 28, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Note 3 – Property and Equipment, Net

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed primarily under the straight-line method over the estimated useful life. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Property and equipment, including related estimated useful lives, consisted of the following:

		December 28,		December 29,
		2019		2018
Land		$	18,030	$	17,985
Buildings and permanent improvements			121,823		127,012
Leasehold improvements			104,089		103,929
Machinery and warehouse equipment			124,640		108,249
Furniture, fixtures and other			99,083		120,693
Computer equipment and software			330,926		427,237
			798,591		905,105
Less accumulated depreciation			(468,946)		(590,884)
	Property and equipment, net	$	329,645	$	314,221

		Estimated Useful
		Lives (in years)
Buildings and permanent improvements		40
Machinery and warehouse equipment		5-10
Furniture, fixtures and other		3-10
Computer equipment and software		3-10

Property and equipment related depreciation expense for the years ended December 28, 2019, December 29, 2018 and December 30, 2017 was $64.4 million, $58.1 million and $54.7 million.

Goodwill and Other Intangibles, Net - Amortization (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to definite-lived intangible assets	$ 108.3	$ 75.3	$ 70.3
Annual amortization expense expected for 2019	102.7
Annual amortization expense expected for 2020	95.6
Annual amortization expense expected for 2021	81.4
Annual amortization expense expected for 2022	73.7
Annual amortization expense expected for 2023	$ 59.3

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Income Taxes [Abstract]
Effective tax rate (in hundredths)	23.40%	20.00%	49.10%
Effective tax rate without the effect of income tax expense (as a percent)			26.40%
Effect of Tax Cuts and Jobs Act [Abstract]
Tax on global intangible low-taxed income ("GILTI")	$ 3,917,000	$ 7,599,000	$ 0
Revaluation of deferred tax assets and liabilities	0	(1,676,000)	2,953,000
Provision for (benefit from) transitional tax	0	(10,000,000)	140,000,000
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current	$ 9,900,000	94,900,000	104,200,000
Tax Cuts and Jobs Act, Accounting Complete [true false]	true
Tax Cuts and Jobs Act, Accounting Complete, Date	Dec. 29, 2018
Unrecognized tax benefits	$ 109,100,000
Unrecognized tax benefits that would affect the effective tax rate if recognized	91,200,000
Total interest	18,000,000.0	15,600,000
Total penalties	0	0	0
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 2,200,000	$ 3,600,000	$ (2,900,000)

Income Taxes (Tables)

12 Months Ended

Dec. 28, 2019

Income Taxes [Abstract]

Income before taxes, equity in earnings of affiliates and loss on sale of equity investment

		Years ended
		December 28,		December 29,		December 30,
		2019		2018		2017
Domestic		$	507,003	$	405,289	$	526,586
Foreign			173,304		131,547		103,208
	Total	$	680,307	$	536,836	$	629,794

Provision for income taxes attributable to continuing operations

The provisions for income taxes were as follows:

				Years ended
				December 28,		December 29,		December 30,
				2019		2018		2017
Current income tax expense:
	U.S. Federal			$	93,418	$	71,854	$	247,254
	State and local				28,150		22,533		19,489
	Foreign				42,004		38,433		41,043
		Total current			163,572		132,820		307,786

Deferred income tax expense (benefit):
	U.S. Federal				5,633		206		12,927
	State and local				1,597		(1,622)		1,621
	Foreign				(11,287)		(23,972)		(13,359)
		Total deferred			(4,057)		(25,388)		1,189
			Total provision	$	159,515	$	107,432	$	308,975

Tax effects of temporary differences to deferred income tax asset (liability)

The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows:

			Years Ended
			December 28,		December 29,
			2019		2018

Deferred income tax asset:
	Investment in partnerships		$	1,420	$	4,150
	Net operating losses and other carryforwards			43,663		43,754
	Inventory, premium coupon redemptions and accounts receivable
		valuation allowances		23,808		25,008
	Stock-based compensation			14,075		14,880
	Uniform capitalization adjustment to inventories			7,259		8,189
	Other asset			35,419		38,806
	Total deferred income tax asset			125,644		134,787
	Valuation allowance for deferred tax assets (1)			(20,699)		(22,403)
	Net deferred income tax asset			104,945		112,384
Deferred income tax liability
	Intangibles amortization			(135,754)		(103,309)
	Property and equipment			(10,555)		(13,075)
	Total deferred tax liability			(146,309)		(116,384)
Net deferred income tax asset (liability)			$	(41,364)	$	(4,000)


(1)	Primarily relates to operating losses of acquired subsidiaries, the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense in accordance with the provisions of ASC Topic 805, “Business Combinations.”

Reconciliation of income tax provision at federal statutory rate to total income tax provision

		Years ended
		December 28,		December 29,		December 30,
		2019		2018		2017
Income tax provision at federal statutory rate		$	142,865	$	112,735	$	220,427
State income tax provision, net of federal income tax effect			16,539		15,872		10,320
Foreign income tax benefit			(4,580)		(2,558)		(19,486)
Pass-through noncontrolling interest			(3,931)		(2,700)		(1,465)
Valuation allowance			(79)		2,017		1,629
Unrecognized tax benefits and audit settlements			3,671		2,126		4,196
Interest expense related to loans			(5,498)		(11,700)		(18,492)
Excess tax benefits related to stock compensation			(86)		(1,008)		(16,964)
Transition tax on deemed repatriation of foreign earnings			-		(10,000)		140,000
Revaluation of deferred tax assets and liabilities			-		(1,676)		2,953
Tax on global intangible low-taxed income ("GILTI")			3,917		7,599		-
Tax benefit related to legal entity reorganization outside the U.S.			-		(13,852)		-
Tax charge related to reorganization of legal entities related
to forming Henry Schein One			-		3,914		-
Tax charge (credit) related to reorganization of legal entities
completed in preparation for the Animal Health spin-off			(1,333)		3,135		-
Other			8,030		3,528		(14,143)
	Total income tax provision	$	159,515	$	107,432	$	308,975

Reconciliation of unrecognized tax benefits excluding the effect of deferred taxes

	December 28,		December 29,		December 30,
	2019		2018		2017
Balance, beginning of period	$	77,800	$	83,200	$	82,200
Additions based on current year tax positions		4,900		5,000		8,500
Additions based on prior year tax positions		17,300		9,400		5,400
Reductions based on prior year tax positions		(1,000)		(1,600)		(800)
Reductions resulting from settlements with taxing authorities		(4,200)		(1,600)		(10,500)
Reductions resulting from lapse in statutes of limitations		(3,700)		(16,600)		(1,600)
Balance, end of period	$	91,100	$	77,800	$	83,200

Commitments and Contingencies

12 Months Ended

Dec. 28, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 20 – Commitments and Contingencies

Purchase Commitments

In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the availability of products for distribution. Future minimum annual payments for inventory purchase commitments as of December 28, 2019 were:

2020		$	403,241
2021			208,200
2022			110,800
2023			-
2024			-
Thereafter			-
	Total minimum inventory purchase commitment payments	$	722,241

Employment, Consulting and Non-Compete Agreements

We have definite-lived employment, consulting and non-compete agreements that have varying base aggregate annual payments for the years 2020 through 2024 and thereafter of approximately $16.8 million, $6.3 million, $4.5 million, $0.9 million, $0.9 million, and $1.7 million, respectively. We also have lifetime consulting agreements that provide for current compensation of $0.4 million per year, increasing $25 every fifth year with the next increase in 2022. In addition, some agreements have provisions for additional incentives and compensation.

Litigation

On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer seeks damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017, Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.

On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme

Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020. We intend to defend ourselves vigorously against this action.

On August 17, 2017, IQ Dental Supply, Inc. (“IQ Dental”) filed a complaint in the U.S. District Court for the Eastern District of New York, entitled IQ Dental Supply, Inc. v. Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company, Case No. 2:17-cv-4834. Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental (“SourceOne”). SourceOne had previously brought an antitrust lawsuit against Henry Schein, Patterson and Benco, which Henry Schein settled in the second quarter of 2017 and which is described in our prior filings with the SEC.

IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted the defendants’ motion to dismiss. On January 19, 2018, IQ Dental appealed the District Court’s order. On May 10, 2019, the U.S. Court of Appeals for the Second Circuit affirmed in part and reversed in part the District Court’s dismissal of the complaint, holding that IQ Dental lacks antitrust standing to challenge the alleged boycott of SourceOne and state dental associations, but that it has standing to challenge injury related to the alleged direct boycott of its business. On June 29, 2019, the Second Circuit denied IQ Dental’s petition for rehearing or rehearing en banc. On January 8, 2020, Henry Schein and IQ Dental entered into a settlement agreement, pursuant to which Henry Schein paid an amount which is not material. Henry Schein was dismissed from the case on January 16, 2020.

On February 12, 2018, the United States Federal Trade Commission (“FTC”) filed a complaint against Benco Dental Supply Co., Henry Schein, Inc. and Patterson Companies, Inc. The FTC alleged, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement, to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners. The FTC alleged that defendants conspired in violation of Section 5 of the FTC Act. The complaint sought equitable relief only and does not seek monetary damages. We denied the allegation that we conspired to refuse to provide discounts to or otherwise serve dental buying groups. A hearing before an administrative law judge began on October 16, 2018 and the hearing record was closed on February 21, 2019. On October 7, 2019, the administrative law judge issued his Initial Decision, finding in relevant part that the “evidence fails to prove a conspiracy involving Schein,” and dismissing the complaint as to Henry Schein. The Initial Decision became the decision of the FTC on November 7, 2019 and is not subject to further appeal.

On March 7, 2018, Joseph Salkowitz, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Stanley M. Bergman and Steven Paladino in the U.S. District Court for the Eastern District of New York, Case No. 1:18-cv-01428. The complaint sought to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased Henry Schein securities from March 7, 2013 through February 12, 2018 (the “Class Period”). The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, including matters relating to the issues in the In re Dental Supplies Antitrust Litigation which Henry Schein settled and which the court dismissed in June 2019, as described in our prior filings with the SEC, and the FTC action described above, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities. The complaint sought unspecified monetary damages and a jury trial. Pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), the court appointed lead plaintiff and lead counsel on June 22, 2018 and recaptioned the putative class action as In re Henry Schein, Inc. Securities Litigation, under the same case number. Lead plaintiff filed a consolidated class action complaint on September 14, 2018. The consolidated class action complaint asserts similar claims against the same defendants (plus Timothy Sullivan) on behalf of the same putative class of purchasers during the Class Period. It alleges that Henry Schein’s stock price was inflated during that period because Henry Schein had misleadingly portrayed its dental-distribution business “as successfully producing excellent profits while operating in a highly competitive environment” even though, “in reality, [Henry Schein] had engaged for years in collusive and anticompetitive practices in order to maintain Schein’s margins, profits, and market share.” The complaint alleges that the stock price started to fall from August 8, 2017, when the company announced below-expected financial performance that allegedly “revealed that Schein’s poor results were a product of abandoning prior attempts to inflate sales volume and margins through anticompetitive collusion,” through February 13, 2018, after the FTC filed a complaint against Benco, Henry Schein and Patterson alleging that they violated U.S. antitrust laws. The complaint alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 and Section 20(a) of the Exchange Act. On September 27, 2019, the court issued a decision partially granting and partially denying defendants’ motion to dismiss the securities action. The court dismissed all claims against Messrs. Bergman and Paladino as well as the Section 10(b) claim against Henry Schein to the extent that that claim relied on the Company’s financial results and margins to allege a material misstatement or omission. The court also dismissed the Section 10(b) claim against Henry Schein to the extent that it relied on the Company’s August 8, 2017 disclosure to allege loss causation. The court otherwise denied the motion as to Henry Schein and Mr. Sullivan. Henry Schein and Mr. Sullivan moved for partial reconsideration of the court’s decision. Pursuant to all parties’ request, the court temporarily took the motion off the calendar after it was fully briefed. The parties have agreed to a resolution of this matter, subject to various conditions, including the drafting and execution of a definitive settlement agreement and court approval. The contemplated settlement, if finally approved, would have no earnings impact to the Company as all payments would be covered by insurance. Henry Schein had previously received a request under 8 Del. C. § 220 to inspect corporate books and records relating to the issues raised in the securities class action and the antitrust matters discussed above.

On May 3, 2018, a purported class action complaint, Marion Diagnostic Center, LLC, et al. v. Becton, Dickinson, and Co., et al., Case No. 3:18-cv-010509, was filed in the U.S. District Court for the Southern District of Illinois against Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton Distributor Co-Conspirators. The complaint alleges that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels. The named plaintiffs seek to represent three separate classes consisting of all health care providers that purchased (i) Becton’s conventional syringes, (ii) Becton’s safety syringes, or (iii) Becton’s safety catheters directly from Becton, Premier, Vizient, Cardinal, O&M or Henry Schein on or after May 3, 2014. The complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, treble damages, reasonable attorneys’ fees and costs and expenses, and pre-judgment and post-judgment interest. On June 15, 2018, an amended

complaint was filed asserting the same allegations against the same parties and adding McKesson Medical-Surgical, Inc. as a defendant. On November 30, 2018, the District Court granted defendants’ motion to dismiss and entered a final judgment, dismissing plaintiffs’ complaint with prejudice. On December 27, 2018, plaintiffs appealed the District Court’s decision to the Seventh Circuit Court of Appeals. The parties argued the appeal on September 27, 2019 and are currently awaiting the Seventh Circuit’s ruling.

On May 29, 2018, an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County alleges that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation dedicated to making grants to programs within Summit County focused on (i) educating the community on alternative pain management treatment techniques and/or avoiding addiction; ‎(ii) supporting research into alternative pain management techniques and protocols; (iii) enabling professionals to obtain the necessary certification for a Medication Assisted Treatment (MAT) Waiver; and (iv) advancing programs and services to Summit County to deliver results and solutions to the opiate and addiction crises. Henry Schein paid $250,000 of Summit County’s expenses.

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have currently been named as a defendant in multiple lawsuits (currently less than one-hundred and twenty-five (125)), which allege claims similar to those alleged in the County of Summit Action. At this time, the only case set for trial is the action filed by Tuscon Medical Center, which is currently scheduled for a 30-day trial beginning on March 16, 2021. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. Of Henry Schein’s 2018 revenue of $9.4 billion from continuing operations, sales of opioids represented less than one-tenth of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

On January 29, 2019, a purported class action complaint was filed by R. Lawrence Hatchett, M.D. against Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators in the U.S. District Court for the Southern District of Illinois. The complaint alleges that members of the proposed class suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged Illinois dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the class. Subject to certain exclusions, the complaint defines the class as “all persons residing in Illinois purchasing and/or reimbursing for dental care provided by independent Illinois dental practices purchasing dental supplies from the defendants, or purchasing from buying groups purchasing these supplies from the defendants, on or after January 29, 2015.” The complaint alleges violations of the Illinois Antitrust Act, 740 Ill. Comp. Stat. §§ 10/3(2), 10/7(2), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. On February 13, 2020, the court granted our motion to dismiss for lack of standing, and dismissed the action with prejudice.

On September 30, 2019, City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York,

Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead counsel on December 23, 2019. We intend to defend ourselves vigorously against this action.

On November 15, 2019, Frank Finazzo filed a putative shareholder derivative action on behalf of Henry Schein, Inc. against various present and former directors and officers of Henry Schein in the U.S. District Court for the Eastern District of New York, Case No. 1:19-cv-6485-LDH-JO. The named defendants in the action are Stanley M. Bergman, Steven Paladino, Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph L. Herring, Donald J. Kabat, Kurt Kuehn, Philip A. Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews, Mark E. Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares, and Louis W. Sullivan, with Henry Schein named as a nominal defendant. The Complaint asserts claims under the federal securities laws and state law relating to the allegations in the antitrust actions, the In re Henry Schein, Inc. Securities Litigation, and the City of Hollywood securities class action described above. The complaint seeks declaratory, injunctive, and monetary relief on behalf of Henry Schein. On January 6, 2020, counsel who filed the Finazzo case filed another, virtually identical putative shareholder derivative action on behalf of Henry Schein against the same defendants, asserting the same claims and seeking the same relief. That case, captioned Mark Sloan v. Stanley M. Bergman, et al., is also pending in the U.S. District Court for the Eastern District of New York, Case No. 1:20-cv-0076. On January 24, 2020, the court consolidated the Finazzo and Sloan cases under the new caption In re Henry Schein, Inc. Derivative Litigation, No. 1:19-cv-06485-LDH-JO, and appointed the counsel in these cases as co-lead counsel for the consolidated action. The parties have agreed to a resolution of this matter subject to various conditions, including the drafting and execution of a definitive settlement agreement and court approval. The contemplated settlement, if finally approved, would involve the adoption of certain procedures but would not involve the payment of any money except a fee to the plaintiffs’ attorneys that is immaterial.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of December 28, 2019, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended		12 Months Ended
Supplemental Cash Flow Information (Details) - USD ($)	Dec. 29, 2018	Sep. 29, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Supplemental Cash Flow Information [Abstract]
Interest			$ 54,685,000	$ 69,371,000	$ 46,985,000
Income taxes			177,277,000	236,479,000	214,135,000
Unrealized gain (loss) from foreign currency hedging activities			(4,911,000)	1,022,000	(1,515,000)
Debt assumed as part of acquisitions			$ 0.0	0.0	$ 300,000
Noncash or Part Noncash Acquisitions [Line Items]
Business Acquisition, non-cash transaction				$ 16,800,000
Henry Schein One, LLC. [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Deferred additional ownership interest	$ 160,600,000
Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Business Acquisition, non-cash transaction		$ 390,300,000
Internet Brands Inc [Member] \| Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Noncash or Part Noncash Acquisition, Interest Acquired		26.00%
Achievement of certain operating targets [Member] \| Henry Schein One, LLC. [Member] \| Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Noncash or Part Noncash Acquisition, Interest Acquired		9.20%

Goodwill and Other Intangibles, Net - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Goodwill [Roll Forward]
Beginning balance	$ 2,081,029	$ 1,553,582
Adjustments to goodwill: Acquisitions	388,628	568,912
Adjustments to goodwill: Foreign currency translation	(7,162)	(41,465)
Ending balance	2,462,495	2,081,029
Health Care Distribution [Member]
Goodwill [Roll Forward]
Beginning balance	1,433,412	1,431,680
Adjustments to goodwill: Acquisitions	50,276	38,848
Adjustments to goodwill: Foreign currency translation	(6,969)	(37,116)
Ending balance	1,476,719	1,433,412
Technology and Value-Added Services [Member]
Goodwill [Roll Forward]
Beginning balance	647,617	121,902
Adjustments to goodwill: Acquisitions	338,352	530,064
Adjustments to goodwill: Foreign currency translation	(193)	(4,349)
Ending balance	$ 985,776	$ 647,617

Segment and Geographic Data

12 Months Ended

Dec. 28, 2019

Segment Reporting [Abstract]

Segment and Geographic Data

Note 18 – Segment and Geographic Data

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 31 countries worldwide.

Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners.

The following tables present information about our reportable and operating segments:


			Years Ended
			December 28,		December 29,		December 30,
			2019		2018		2017
Net Sales:
	Health care distribution ⁽¹⁾
		Dental	$	6,415,865	$	6,347,998	$	6,047,811
		Medical		2,973,586		2,661,166		2,497,994
		Total health care distribution		9,389,451		9,009,164		8,545,805
	Technology and value-added services ⁽²⁾			515,085		408,439		337,633
		Total excluding Corporate TSA revenues		9,904,536		9,417,603		8,883,438
	Corporate TSA revenues ⁽³⁾			81,267		-		-
		Total	$	9,985,803	$	9,417,603	$	8,883,438

(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
	generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
	and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and
	other services.

(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection
	with the Animal Health Spin-off, which we expect to continue through August 2020.

			Years ended
			December 28,		December 29,		December 30,
			2019		2018		2017
Operating Income:
	Health care distribution		$	591,404	$	490,988	$	561,888
	Technology and value-added services			126,857		109,631		107,873
		Total	$	718,261	$	600,619	$	669,761

Income before taxes and equity in earnings of affiliates:
	Health care distribution		$	553,181	$	429,429	$	526,255
	Technology and value-added services			127,126		107,407		103,539
		Total	$	680,307	$	536,836	$	629,794

Depreciation and Amortization:
	Health care distribution		$	146,960	$	122,767	$	116,260
	Technology and value-added services			37,982		20,863		17,595
		Total	$	184,942	$	143,630	$	133,855

Income Tax Expense:
	Health care distribution		$	129,381	$	53,660	$	271,920
	Technology and value-added services			30,134		53,772		37,055
		Total	$	159,515	$	107,432	$	308,975

Interest Income:
	Health care distribution		$	15,352	$	15,106	$	12,236
	Technology and value-added services			405		385		202
		Total	$	15,757	$	15,491	$	12,438

Interest Expense:
	Health care distribution		$	50,666	$	76,006	$	51,039
	Technology and value-added services			126		10		27
		Total	$	50,792	$	76,016	$	51,066

Purchases of Fixed Assets:
	Health care distribution		$	69,095	$	68,577	$	59,865
	Technology and value-added services			7,124		2,706		2,539
		Total	$	76,219	$	71,283	$	62,404

			As of
			December 28,		December 29,		December 30,
			2019		2018		2017
Total Assets:
	Health care distribution		$	5,822,057	$	5,289,348	$	5,336,320
	Technology and value-added services			1,329,044		994,506		334,977
	Discontinued operations			-		2,216,673		2,192,698
		Total	$	7,151,101	$	8,500,527	$	7,863,995

The following table presents information about our operations by geographic area as of and for the three years ended December 28, 2019. Net sales by geographic area are based on the respective locations of our subsidiaries. No country, except for the United States, generated net sales greater than 10% of consolidated net sales. There were no material amounts of sales or transfers among geographic areas and there were no material amounts of export sales.

		2019				2018				2017
		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets
United States		$	6,876,194	$	2,400,733	$	6,411,558	$	1,855,788	$	6,039,613	$	1,208,351
Other			3,109,609		1,195,947		3,006,045		915,493		2,843,825		1,072,849
	Consolidated total	$	9,985,803	$	3,596,680	$	9,417,603	$	2,771,281	$	8,883,438	$	2,281,200

Segment and Geographic Data (Details)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 28, 2019

USD ($)

countries

Sep. 28, 2019

USD ($)

Jun. 29, 2019

USD ($)

Mar. 30, 2019

USD ($)

Dec. 29, 2018

USD ($)

Sep. 29, 2018

USD ($)

Jun. 30, 2018

USD ($)

Mar. 31, 2018

USD ($)

Dec. 28, 2019

USD ($)

number

countries

Dec. 29, 2018

USD ($)

Dec. 30, 2017

USD ($)

Number of reportable segments | number

Number of countries served globally | countries

Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment

$ 2,668,941

$ 2,508,767

$ 2,447,827

$ 2,360,268

$ 2,472,556

$ 2,355,565

$ 2,316,032

$ 2,273,450

$ 9,985,803

$ 9,417,603

$ 8,883,438

Operating income

196,334

$ 187,198

$ 162,288

$ 172,441

158,002

$ 123,269

$ 157,108

$ 162,240

718,261

600,619

669,761

680,307

536,836

629,794

Depreciation and amortization

184,942

143,630

133,855

Income taxes

159,515

107,432

308,975

Interest income

15,757

15,491

12,438

Interest expense

50,792

76,016

51,066

Purchases of fixed assets

76,219

71,283

62,404

Discontinued operations [Member]

7,151,101

8,500,527

7,151,101

8,500,527

7,863,995

Total excluding Corporate TSA revenues

2,216,673

2,192,698

Health Care Distribution [Member]

9,904,536

^[1]

9,417,603

^[1]

8,883,438

Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment

9,389,451

9,009,164

8,545,805

Operating income

591,404

490,988

561,888

553,181

429,429

526,255

Depreciation and amortization

146,960

122,767

116,260

Income taxes

129,381

53,660

271,920

Interest income

15,352

15,106

12,236

Interest expense

50,666

76,006

51,039

Purchases of fixed assets

69,095

68,577

59,865

Health Care Distribution [Member] | Dental [Member]

5,822,057

5,289,348

5,822,057

5,289,348

5,336,320

Health Care Distribution [Member] | Medical [Member]

6,415,865

6,347,998

6,047,811

Technology and Value-Added Services [Member]

2,973,586

2,661,166

2,497,994

Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment

515,085

408,439

337,633

Operating income

126,857

109,631

107,873

127,126

107,407

103,539

Depreciation and amortization

37,982

20,863

17,595

Income taxes

30,134

53,772

37,055

Interest income

405

385

202

Interest expense

126

Purchases of fixed assets

7,124

2,706

2,539

$ 1,329,044

$ 994,506

1,329,044

994,506

334,977

Corporate TSA [Member]

Corporate TSA [Member] | Animal Health [Member]

81,267

$ 0

Temporary Equity Disclosure [Abstract]

^[1]

$ 81,267

$ 0

[1]

(1)

Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement

entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2016	$ 2,800,804	$ 1,588	$ 126,742	$ 2,981,777	$ (317,041)	$ 7,738
Beginning Balance (in shares) at Dec. 31, 2016		158,805,010
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	407,090	$ 0	0	406,299	0	791
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	184,425	0	0	0	183,773	652
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(729)	0	0	0	(729)	0
Unrealized investment gain (loss), net of tax impact	(3)	0	0	0	(3)	0
Pension adjustment gain (loss), net of tax impact	3,933	0	0	0	3,933	0
Dividends paid	(546)	0	0	0	0	(546)
Other adjustments	399	0	23	0	0	376
Purchase of noncontrolling interests	4,150	0	0	0	0	4,150
Change in fair value of redeemable securities	(162,729)	0	(162,729)	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	8,050	0	0	0	0	8,050
Repurchase and retirement of common stock - Value	(450,000)	$ (59)	(97,205)	(352,736)	0	0
Repurchase and retirement of common stock - Shares		(5,864,404)
Stock issued upon exercise of stock options, Value	5,266	$ 2	5,264	0	0	0
Stock issued upon exercise of stock options, shares		197,434,000
Stock-based compensation expense - Value	(42,294)	$ (11)	(42,283)	0	0	0
Stock-based compensation expense - Shares		1,072,922
Shares withheld for payroll taxes - Value	(44,776)	$ (5)	(44,771)	0	0	0
Shares withheld for payroll taxes - Shares		(520,816)
Settlement of stock-based compensation awards	(599)	$ 0	(599)	0	0	0
Settlement of stock-based compensation awards, shares		0
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	35,681	$ 0	35,681	0	0	0
Transfer of charges in excess of captial	0	0	95,311	(95,311)	0	0
Ending Balance at Dec. 30, 2017	2,824,410	$ 1,537	0	2,940,029	(130,067)	12,911
Ending Balance (in shares) at Dec. 30, 2017		153,690,146
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	540,278	$ 0	0	535,881	0	4,397
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(123,325)	0	0	0	(122,360)	(965)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	626	0	0	0	626	0
Unrealized investment gain (loss), net of tax impact	(3)	0	0	0	(3)	0
Pension adjustment gain (loss), net of tax impact	3,033	0	0	0	3,033	0
Dividends paid	(656)	0	0	0	0	(656)
Other adjustments	694	0	(19)	0	0	713
Purchase of noncontrolling interests	(214)	0	0	0	0	(214)
Change in fair value of redeemable securities	(148,919)	0	(148,919)	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	564,270	0	0	0	0	564,270
Repurchase and retirement of common stock - Value	(200,000)	$ (25)	(36,206)	(163,769)	0	0
Repurchase and retirement of common stock - Shares		(2,518,387)
Stock issued upon exercise of stock options, Value	3,076	$ 1	3,075	0	0	0
Stock issued upon exercise of stock options, shares		153,516
Stock-based compensation expense - Value	(36,240)	$ (4)	(36,236)	0	0	0
Stock-based compensation expense - Shares		340,794
Shares withheld for payroll taxes - Value	(18,143)	$ (3)	(18,140)	0	0	0
Shares withheld for payroll taxes - Shares		(267,772)
Settlement of stock-based compensation awards	(727)	$ 0	(727)	0	0	0
Settlement of stock-based compensation awards, shares		3,371
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	58,554	$ 0	58,554	0	0	0
Transfer of charges in excess of captial	0	0	106,146	(106,146)	0	0
Ending Balance at Dec. 29, 2018	$ 3,541,788	$ 1,514	0	3,208,589	(248,771)	580,456
Ending Balance (in shares) at Dec. 29, 2018	151,401,668	151,401,668
Cumulative impact of adopting new accounting standards	$ 2,594	$ 0	0	2,594	0	0
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	704,666	0	0	694,734	0	9,932
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(2,327)	0	0	0	(2,222)	(105)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(3,876)	0	0	0	(3,876)	0
Unrealized investment gain (loss), net of tax impact	12	0	0	0	12	0
Pension adjustment gain (loss), net of tax impact	(5,924)	0	0	0	(5,924)	0
Dividends paid	(535)	0	0	0	0	(535)
Other adjustments	(3)	0	(3)	0	0	0
Change in fair value of redeemable securities	7,300	0	7,300	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	42,345	0	0	0	0	42,345
Adjustment for Animal Health Spin-off, Value	1	$ 1	0	0	0	0
Adjustment to stock for Spin-off transaction, Shares		87,629,000
Repurchase and retirement of common stock - Value	(525,000)	$ (82)	(79,785)	(445,133)	0	0
Repurchase and retirement of common stock - Shares		(8,173,912)
Stock issued upon exercise of stock options, Value	34	$ 0	34	0	0	0
Stock issued upon exercise of stock options, shares		2,526
Stock-based compensation expense - Value	(45,245)	$ (2)	(45,243)	0	0	0
Stock-based compensation expense - Shares		215,408
Shares withheld for payroll taxes - Value	(10,845)	$ (1)	(10,844)	0	0	0
Shares withheld for payroll taxes - Shares		(179,860)
Settlement of stock-based compensation awards	160	$ 0	160	0	0	0
Settlement of stock-based compensation awards, shares		0
Share Sale related to Animal Health business	361,090	$ 0	361,090	0	0	0
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	(523,720)	0	(73,970)	(543,158)	93,408	0
Transfer of charges in excess of captial	0	0	(201,457)	201,457	0	0
Ending Balance at Dec. 28, 2019	$ 3,630,137	$ 1,434	47,768	3,116,215	(167,373)	632,093
Ending Balance (in shares) at Dec. 28, 2019	143,353,459	143,353,459
Cumulative impact of adopting new accounting standards	$ (274)	$ 0	$ 0	$ (274)	$ 0	$ 0

Redeemable Noncontrolling Interests (Tables)

12 Months Ended

Dec. 28, 2019

Change in fair value of redeemable noncontrolling interests

		December 28,		December 29,		December 30,
		2019		2018		2017
Balance, beginning of period		$	219,724	$	465,585	$	285,567
Decrease in redeemable noncontrolling interests due to
	redemptions		(2,270)		(287,767)		(22,294)
Increase in redeemable noncontrolling interests due to
	business acquisitions		74,865		4,655		72,291
Net income attributable to redeemable noncontrolling interests			14,838		15,327		24,513
Dividends declared			(10,264)		(8,206)		(7,680)
Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		(2,335)		(11,330)		4,530
Change in fair value of redeemable securities			(7,300)		41,460		108,658
Balance, end of period		$	287,258	$	219,724	$	465,585

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 28, 2019

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Schedule II

Valuation and Qualifying Accounts

(in thousands)

					Additions (Reductions)
							Charged
			Balance at		Charged to		(credited) to				Balance at
			beginning of		statement of		other				end of
Description			period		income (1)		accounts (2)		Deductions (3)		period

Year ended December 28, 2019:
	Allowance for doubtful accounts
		and other	$	53,121	$	12,612	$	134	$	(5,865)	$	60,002

Year ended December 29, 2018:
	Allowance for doubtful accounts
		and other	$	46,261	$	14,384	$	(1,158)	$	(6,366)	$	53,121

Year ended December 30, 2017:
	Allowance for doubtful accounts
		and other	$	33,150	$	7,915	$	11,341	$	(6,145)	$	46,261

(1)	Represents amounts charged to bad debt expense.

(2)	Amounts charged (credited) to other accounts primarily relate to provision for late fees and the impact of foreign currency exchange rates.

(3)	Deductions primarily consist of fully reserved accounts receivable that have been written off.

Quarterly Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 29, 2018	Sep. 29, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Quarterly Financial Data [Abstract]
Net sales	$ 2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	$ 2,472,556	$ 2,355,565	$ 2,316,032	$ 2,273,450	$ 9,985,803	$ 9,417,603	$ 8,883,438
Gross profit	810,598	761,167	767,431	751,690	750,931	722,359	718,328	719,129	3,090,886	2,910,747	2,746,662
Litigation settlements					0	38,488	0	0	0	38,488	5,325
Restructuring costs	(1,059)	(802)	11,925	4,641	34,644	8,551	8,497	2,675	14,705	54,367	0
Operating income	196,334	187,198	162,288	172,441	158,002	123,269	157,108	162,240	718,261	600,619	669,761
Net gain (loss) on sale of equity investments	186,769	0	0	0					186,769	0	(17,636)
Net income	337,192	143,212	121,417	123,640	124,886	96,247	114,591	114,717	719,138	562,126	459,293
Amounts attributable to Henry Schein, Inc.:
Net income	$ 330,609	$ 134,916	$ 116,753	$ 118,413	$ 117,777	$ 90,770	$ 110,636	$ 111,534	$ 694,734	$ 535,881	$ 406,299
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 2.27	$ 0.92	$ 0.79	$ 0.79	$ 0.78	$ 0.60	$ 0.72	$ 0.73	$ 4.70	$ 3.51	$ 2.59
Diluted (in dollars per share)	$ 2.25	$ 0.91	$ 0.78	$ 0.78	$ 0.77	$ 0.59	$ 0.72	$ 0.72	$ 4.65	$ 3.49	$ 2.57

Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
Earnings Per Share (Details) - shares shares in Thousands	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Weighted-average common shares outstanding:
Basic (in shares)	147,817	152,656	156,787
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units (in shares)	1,440	1,051	1,421
Diluted (in shares)	149,257	153,707	158,208

Fair Value Measurements (Tables)

12 Months Ended

Dec. 28, 2019

Fair Value Measurements [Abstract]

Fair value - assets and liabilities measured and recognized on a recurring basis

			December 28, 2019
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	567	$	-	$	567
		Total assets	$	-	$	567	$	-	$	567

Liabilities:
	Derivative contracts		$	-	$	5,795	$	-	$	5,795
		Total liabilities	$	-	$	5,795	$	-	$	5,795

Redeemable noncontrolling interests			$	-	$	-	$	287,258	$	287,258

			December 29, 2018
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	12,533	$	-	$	12,533
		Total assets	$	-	$	12,533	$	-	$	12,533

Liabilities:
	Derivative contracts		$	-	$	1,708	$	-	$	1,708
		Total liabilities	$	-	$	1,708	$	-	$	1,708

Redeemable noncontrolling interests			$	-	$	-	$	219,724	$	219,724

Comprehensive Income - Foreign Currency Translation Gain (Loss) Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation gain (loss)	$ (4,070)	$ (136,356)	$ 191,886

Revenue from Contracts with Customers - Disaggregation of Net sales (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 28, 2019

Sep. 28, 2019

Jun. 29, 2019

Mar. 30, 2019

Dec. 29, 2018

Sep. 29, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 28, 2019

Dec. 29, 2018

Dec. 30, 2017

$ 2,668,941

$ 2,508,767

$ 2,447,827

$ 2,360,268

$ 2,472,556

$ 2,355,565

$ 2,316,032

$ 2,273,450

$ 9,985,803

$ 9,417,603

$ 8,883,438

North America [Member]

7,255,298

6,792,035

International [Member]

Total excluding Corporate TSA revenues

2,730,505

2,625,568

Total excluding Corporate TSA revenues | North America [Member]

9,904,536

^[1]

9,417,603

^[1]

8,883,438

Total excluding Corporate TSA revenues | International [Member]

^[1]

7,251,200

6,792,035

Healthcare Distribution [Member]

^[1]

2,653,336

2,625,568

Healthcare Distribution [Member] | North America [Member]

9,389,451

9,009,164

8,545,805

Healthcare Distribution [Member] | International [Member]

6,805,883

6,447,867

Healthcare Distribution [Member] | Dental [Member]

2,583,568

2,561,297

Healthcare Distribution [Member] | Dental [Member] | North America [Member]

6,415,865

6,347,998

6,047,811

Healthcare Distribution [Member] | Dental [Member] | International [Member]

3,911,746

3,866,171

Healthcare Distribution [Member] | Medical [Member]

2,504,119

2,481,827

Healthcare Distribution [Member] | Medical [Member] | North America [Member]

2,973,586

2,661,166

2,497,994

Healthcare Distribution [Member] | Medical [Member] | International [Member]

2,894,137

2,581,696

Technology and Value-Added Services [Member]

79,449

79,470

Technology and Value-Added Services [Member] | North America [Member]

515,085

408,439

337,633

Technology and Value-Added Services [Member] | International [Member]

445,317

344,168

69,768

64,271

Corporate TSA [Member]

Corporate TSA [Member] | Animal Health [Member]

81,267

$ 0

Corporate TSA [Member] | Animal Health [Member] | North America [Member]

^[1]

81,267

Corporate TSA [Member] | Animal Health [Member] | International [Member]

^[1]

4,098